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ABSTRACT 
 
Anthrax is a highly fatal disease caused by the gram-positive, endospore-forming, rod-
shaped bacterium Bacillus anthracis. Spores, rather than the vegetative bacterial cells, are the 
source of anthrax infections. The spores of B. anthracis are enclosed by a prominent loose-fitting 
structure called the exosporium. The exosporium is composed of a basal layer and an external 
hair-like nap. The filaments of the hair-like nap are made up largely of a single collagen-like 
glycoprotein called BclA. A second glycoprotein, BclB, has been identified in the exosporium 
layer. The specific location of this glycoprotein within the exosporium layer and its role in the 
biology of the spore are unknown. We created a mutant strain of B. anthracis ∆Sterne that carries 
a deletion of the bclB gene. Immunofluorescence studies indicated that the mutant strain 
produced spores with increased amounts of the BclA glycoprotein expressed on their surface. 
Differences in exosporium composition between the mutant and wild-type spores were 
identified. The mutant was also found to possess structural defects in the exosporium layer of the 
spore (visualized by electron microscopy, immunofluorescence, and flow cytometry) resulting in 
an exosporium that is more fragile than that of a wild-type spore and is easily lost. The resistance 
properties of the mutant spores were unchanged from that of the wild-type spores. The bclB 
mutation did not affect spore germination or kinetics of spore survival within macrophages.  
BclB plays a key role in the formation and maintenance of a rigid and complete exosporium 
structure in B. anthracis.  BclB plays a key role in the formation and maintenance of the 
exosporium structure in B. anthracis. 
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Literature Review 
 
Introduction 
 
 “For neither might the hides be used, nor could one cleanse the flesh by water or master 
it by fire. They could not even shear the fleeces, eaten up with sores and filth, nor touch the 
rotten web.  Nay, if any man donned the loathsome garb, feverish blisters and foul sweat would 
run along his fetid limbs, and not long had he to wait ere the accursed fire was feeding on his 
stricken limbs.”  
 Virgil: The Georgics III, 30 B.C. 
 
Bacillus anthracis, a spore-forming gram positive bacterium, is the etiological agent of 
anthrax.  The anthrax disease has been described in history as early as the book of Genesis in the 
15th century as the 5th plague that killed the cattle of the Egyptians (160).  Greek, Roman, Hindu, 
and European literature all contain reports of anthrax outbreaks.  Major outbreaks occurred in 
Germany in the 14th century and in Russia during the 17th century.  The diseased animals were 
buried in deep pits to avoid spreading of the contagion to the human populations and other cattle 
in the area. Centuries later the spore-ridden pit could be unearthed by an unsuspecting farmer 
plowing a field and exposing his whole herd to the ages-old anthrax spores.  Most of the more 
modern outbreaks occurred among those with occupations related to livestock and livestock 
byproducts.  Wool workers were very susceptible to the disease due to the large numbers of 
spores inhaled each day from the contaminated wool, and in many areas the disease became 
known as “woolsorter’s disease.”   
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Anthrax, although uncommon in developed countries, is still a threat among developing 
countries.  Anthrax is endemic in Central America, the Caribbean, Spain, Greece, the Middle 
East, and much of Africa.  West Africa is the most affected region in the world with continuous 
outbreaks among both wildlife and humans, with the largest reported outbreak in 1979-1980 
consisting of 10,000 cutaneous anthrax infections.  Annually there are roughly 20,000 to 100,000 
cases of anthrax worldwide (161).   
 
Figure 1: Incidence of Bacillus anthracis outbreaks.  Adapted from the History Magazine, 2002 
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Bacillus anthracis was first described by Davaine, a French parasitologist in 1850.  
Robert Koch and Louis Pasteur, two founding fathers of modern medical microbiology, both 
worked on the ancient pathogen.  In 1888, Koch first described the complete sporulation to 
germination life cycle of anthracis and other spore-formers (1).  Louis Pasteur observed that  
leaving cultures of B. anthracis in the sun caused them to become avirulent.  The cultures threw 
off their virulence plasmids due to the increased temperature, leading Pasteur to develop the 
concept of attenuation and the creation of weakened bacterial vaccines.  These discoveries led to 
the concepts and vaccine design strategies which have saved millions of lives over the years. 
 Although most human cases of anthrax are among people who come in contact with 
animals and animal byproducts, recently some new cases are due to the development of anthrax 
as a biological weapon.  It is an ideal bioterrorism agent, able to be produced in mass quantities 
and covered in a resistant coat to allow it to remain stable, not require refrigeration for storage, 
and maintain virulence for hundreds of years.   Aerosolization of the spores as a means of 
dissemination could have dire consequences, infecting unknown thousands with flu-like 
symptoms and leading to heavy mortality rate.  The World Health Organization estimates that 50 
kg of weapons grade anthrax released by an aircraft over an urban population of 5 million would 
result in 250,000 cases of predominantly inhalation anthrax, and at an economic impact of 26.2 
billion dollars per 100,000 exposed (125).   
Anthrax has been listed as a category A select agent, along with tularemia, smallpox, 
plague, and other pathogens.  The USA, USSR, France, and England have all developed anthrax 
as a weapon of war.  In 1937, the Japanese used B. anthracis spores as a weapon against the 
Chinese, and did extensive testing of the bacterium on Chinese prisoners. Recently, Iraq has also 
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admitted to having an active biological warfare program including anthrax.   The tragic release of 
huge stockpiles of biological weapons grade spores at the Russian town of Sverdlovsk in 1979 
led to 64 deaths in the surrounding populace.  The recent Amerithrax letters in the US lead to 18 
cases of anthrax, 11 inhalational cases of which 5 died, and 7 cutaneous cases.   The 
development of better vaccines to anthrax has been a top priority in many countries over the last 
few years. 
 
General Phenotype/Genotype 
 
Bacillus anthracis is a Gram-positive, non-motile, aerobic spore former.  It is primarily a 
pathogen of ruminants, but occasionally infects humans.  This rod-shaped bacterium contains a 
low G+C DNA content.  When nutrients are scarce, the bacterium produces a centrally located, 
hardy spore that can resist many environmental insults and survive until the environment is again 
suitable for stable growth. The bacterium contains a unique amino acid based capsule.  Bacillus 
anthracis is one of the few bacteria that contain group II introns; novel genetic elements that 
have properties of both catalytic RNAs and retroelements.  They encode reverse transcriptase 
and are either active retroelements, or are derivatives of retroelements, and are able to self-splice 
(60).  Whether the B. anthracis spore is able to germinate and subsequently thrive in the soil is 
still under debate, but a recent study has shown that it can germinate and grow in the rhizosphere 
of some grassy plants (68).   
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Many advances have occurred in the last 30 years in the study of the Bacillus pathogens.  
Although there are numerous Bacillus species, only three have been identified as major 
pathogens.  Bacillus anthracis is primarily a pathogen of ruminants, and its infection is initiated 
upon access of the spores into the body.  Bacillus cereus, genetically related to anthracis, is a 
major food poisoning agent and causal agent of endopthalmitis.  Bacillus thuringiensis is a major 
pathogen of insects with its insecticidal toxins and is currently used as an insect control agent.  
The major difference between B. anthracis and B. cereus remains the presence of two virulence 
plasmids in the B. anthracis strains. Other than the presence of the two virulence plasmids, there 
are about 150 genes that have been shown to differ between B. cereus and B. anthracis.   
 
Differentiation of Strains 
 
 The Bacillus cereus group is one of the most taxonomically similar groups of eubacteria 
(147).  In fact, DNA-DNA hybridization and pulse field electrophoresis have shown great 
homology among B. anthracis, B. thuringiensis, and B. cereus (33).  A recent multilocus enzyme 
electrophoresis study has concluded that the members of this group belong to one species (51).  
Although traditionally the presence of the anthracis plasmids pX01 and pX02 were enough to 
differentiate the species from others of the B. cereus family, recent reports of pX01 and pX02-
like plasmids in B. cereus have led these plasmids to not be reliable in differentiation studies 
(126).  Analysis of the RNA polymerase B subunit genes can partially differentiate B. anthracis 
from its sister species (50).  Differentiation between B. cereus and B. anthracis has also been 
attempted by searching for gamma phage specific for one species of the B. cereus family.  The 
presence of the crystal insecticidal toxins helps differentiate B. thuringiensis from the others 
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strains.  Some strains of Bacillus cereus and Bacillus thuringiensis spores have filamentous 
appendages (48, 57).  Differentiation between strains has also been tried using variability in 
optical chromatographic readings, although this may be due to some of the differences in 
exosporium filaments which are not present in all the species and strains of the various members 
of the Bacillus cereus family (59).  Polymorphism in the BclA exosporium gene has also led to 
the development of a PCR-based test to differentiate Bacillus cereus family members (99). 
 
Virulence Factors 
 
The pX01 plasmid  
The first of the two virulence plasmids in B. anthracis is pX01.  This 181 kb plasmid 
encodes approximately 143 ORFs, including the genes for the production of the three toxin 
components that make up the two anthrax toxins.  The genes responsible for the production of 
the anthrax toxins are pagA (encoding protective antigen), lef (containing lethal factor), and cya 
(encoding edema factor) genes. Although the GC content of 33% would suggest that it is a 
natural Bacillus plasmid  the pX01 plasmid contains a pathogenicity island of 44 kb which is 
surrounded by two insertion elements and several genes predicted to be the result of horizontal 
transfer.  pX01 also encodes gerX, a germination operon that is essential for virulence in mice 
(40, 45).  The anthrax toxin genes have also been found, albeit rarely, in B. cereus respiratory 
infection isolates that contain pX01-like plasmids (126).  These strains have also been found to 
contain polysaccharide capsule clusters on a separate virulence plasmid.    
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Anthrax produces two binary toxin combinations, consisting of a binding component and 
a effector component. The first aspect of the toxin entry into host cells is the binding of 
protective antigen (PA) to a receptor.  It is known as protective antigen because antibodies 
produced against PA protect the animal during experimental infection by blocking access of 
toxins into the cells.  There are actually two anthrax toxin receptors, ANTXR1 and ANTXR2 
(32).  ANTXR1 corresponds to anthrax receptor/tumor endothelial marker 8, and ANTXR2 
corresponds to capillary morphogenesis protein 2.  After the PA binds to one of the receptors on 
susceptible cells it combines into a heptamer in lipid rafts upon the cell membrane (132). The PA 
precursor is a protein of 83,000 molecular weight (PA83).  After insertion into the target cell 
membrane the PA83 heptamer is cleaved by furin or other furin-like proteases to produce a 
63,000 molecular weight protein (PA63)  (162).  The PA63 heptamer now contains a binding 
domain to facilitate the binding of lethal factor and edema factor.  Both lethal factor (LF), the 
product of the lef gene, and edema factor (EF), product of the cya gene, have a common N-
terminal domain that binds to the cleaved PA63 heptamer.  The binding of the PA63 heptamer to 
the lethal or edema factor leads to the complex being brought into the cell by receptor-mediated 
endocytosis by a clathrin-dependent process (133).  As the pH of the endocytic vesicle decreases, 
this acidic environment leads a change in conformation and formation of a pore by the heptamer, 
releasing the edema factor and lethal factors into the cell cytoplasm. The combination of PA and 
LF, called lethal toxin (LT), leads to death in high doses in experimental animals (56).  The 
combination of PA and EF, called edema toxin (ET), leads to production of edema in the skin of 
animals (56).  None of the components alone are toxic, as lethal factor and edema factor can not 
access the cell without PA, which by itself causes no pathology.         
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Lethal Toxin 
 
 Lethal Toxin is a zinc metalloprotease whose target is the N-terminus of MAPKKs, 
MEK1, and MEK2 (196).  It is capable of cleaving all of the various MAPKKs except MEK5, 
and these cleavage events lead to rapid cell lysis by apoptosis in murine macrophages.  It is 
believed that the majority of cellular toxicity associated with anthrax infection is due to this 
intracellular hydrolysis of important host protein substrates (163).  Lethal Factor can also lead to 
the collapse of vasculature and hypoxia.  The characteristic pleural effusions and necrosis of the 
liver, spleen, and bone have all been attributed to the hypoxia-mediated damage due to LT (56). 
 
Edema Toxin 
 
The action of the edema toxin (ET) is dependent upon the host calcium-binding protein 
calmodulin.  ET efficiently converts intracellular ATP into cAMP.  The edema factor adenylate 
cyclase is at least 1,000 fold more active than any of the host adenylate cyclases in cAMP 
production, and leads to large amounts of secreted fluid in cells (56, 112, 164).  Purified ET has 
been shown to inhibit the chemotactic response of polymorphonuclear leukocytes and their 
subsequent phagocytosis (165, 166).  Highly-purified ET can cause death in a BALB/c mouse at 
very low doses and is more lethal than LT.  Purified ET leads to accumulation of fluid in the 
intestines, hemorrhaging of the ileum and adrenal glands, lesions in the lymphoid organs, bone, 
bone marrow, GI mucosa, heart and kidneys; and multiorgan failure (56).  In vitro, ET inhibits 
adhesion of neutrophils, stimulates their apoptosis, and blocks proliferation of lymphocytes 
(112). 
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 In the host it is likely that the two toxins act in synergy to produce all the symptoms of 
anthrax.  Both are produced by 3 hrs after germination and suppress superoxide and NO 
production (118).  In later stages of the disease, lethal levels of toxins induce the development of 
the cytokine-independent shock-like death associated with anthrax (56, 112, 136).  EF and LF 
deficient strains are greatly attenuated.  The cleavage of MEK 1, 2, and 3 in vitro by LF leads to 
activation of macrophages and related signaling would produce cytokines such as TNFα, IL-1, 
and IL-6 (163).  ET inhibits not only induced TNFα secretion but also inhibits phagocytosis and 
oxidative burst activities.  The two toxins function together to induce shock in a rat model (112).  
Mice deficient in macrophages are resistant to LF challenge (124).  Both toxins cause 
hypotension (112).  LT leads to high extravasation of fluid and ET leads to increased cAMP 
levels in cardiac pacemaker cells and decreased heart rate (112).  More on the actions of the two 
toxins, as well as their role in modification of the immune system can be found in the Disease 
Progression section below.   
 
The pX02 plasmid 
 
 The second virulence plasmid in B. anthracis is the 96 kb plasmid pX02, which contains 
the capA, capC, capB, and capD genes responsible for the production of the characteristic poly-
D-glutamic acid capsule. This capsule is produced and surrounds the cell after outgrowth in vivo, 
or in vitro in the presence of bicarbonate, hindering phagocytosis and perhaps playing a role in 
adherence.   The weakly antigenic capsule may act to hide the cells from the adaptive immune 
system.  In addition to the capsule genes, pX02 encodes Dep, a capsule degradation enzyme, and 
 9
several global regulators of virulence.  The first of these regulators is AcpA, which interacts with 
and turns on the capsule biosynthesis genes (129).  The second, AcpB, also turns on the capsule 
biosynthesis genes.  Both the AcpA and AcpB regulators are turned on by the master regulator, 
AtxA.  AtxA is encoded on pX01, and atxA mutants are avirulent (127).  The pX02 plasmid is 
often spontaneously lost, especially during growth at elevated temperatures, such as 42ºC (30). 
 
Virulence Regulation 
 
 Control of virulence gene expression in B. anthracis is highly dependent upon atxA, a 
global virulence regulatory gene located on the virulence plasmid pX01.  In fully virulent strains, 
containing both the pX01 and pX02 plasmids, AtxA acts as a global regulator controlling 
expression of the pX02-encoded capsule biosynthesis genes, capBCAD; as well as the toxin 
structural genes pagA, lef, and cya on the pX01 plasmid (127, 128).  AtxA also controls 
expression of a number of other genes on the chromosome (131).  PagR is a major regulator of 
the pagA, cya, and lef genes. PagR has also been found to affect transcription of the S-layer 
genes and biases the cells in the presence of CO2 to produce the Ea1 S-layer protein over the Sap 
S-layer protein during infection (130).  Regulation of PagR is controlled by AtxA (130, 127).  
This effect may not be direct and is likely the result of intermediate factors (67).  CapD (Dep) is 
a degradative enzyme which can break down the capsule into small D-glutamic acid fragments 
that are secreted from the cell.  AtxA, in the current Koehler model, regulates the capsule genes 
through the pX02 encoded genes acpA and acpB (131).  acpA and acpB isogenic mutants have 
no effect on capsule production, but an acpA/acpB double mutant is completely devoid of 
capsule (129). AcpA and AcpB share substantial amino acid and functional similarities.  For 
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many AtxA-regulated genes, including acpA, acpB, and the toxin genes, expression is greatly 
induced under conditions of high CO2 or bicarbonate. This effect (acpA, 23-fold and acpB, 59-
fold) is greater than can be explained by the bicarbonate induction of atxA alone (2.5-fold), 
suggesting that another regulator or bicarbonate itself upregulates the acpB and acpA promoters 
(66, 131, 129).    
 
This reason for bicarbonate and temperature induction of toxin and capsule genes may be 
from recognition of host surroundings and the necessary induction of toxin production to survive 
and thrive in the host environment.  The concentration of bicarbonate for optimal expression is 
the same concentration that is found in the bloodstream, 48 mM.  Toxin production is also 
regulated by the sporulation regulator Spo0A, which exerts its effect through the regulator AbrB; 
and recently been reported to be regulated by GerH, potentially through Spo0A (155). 
 
S-layer and Capsule 
 
In addition to the usual peptidoglycan and cytoplasmic membrane of most Gram-positive 
bacteria, B. anthracis encodes two other surface layers.  The first layer is formed at the 
outermost point of the cell wall.  A single protein polymer is assembled in a large crystalline 
sheath that surrounds the entire bacterium (7).  The S-layer may play a role in involvement of 
cell shape maintenance, protection from complement, interactions with host macrophages, and in 
molecular sieving (5).  The S-layer is comprised of one of two proteins depending on the growth 
phase of the bacterium.  The protein Sap (surface array protein) is first assembled into the S-
layer during growth, and is slowly replaced during stationary phase with the Ea1 protein 
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(Extractable antigen 1) (6).  The S-layer proteins can comprise 5-10% of the total cell protein (5). 
S-layer proteins have not been found to be important in virulence, as the LD50 in mice doesn’t 
change in the absence of the S-layer, however, they may confer increased resistance to 
complement pathway-mediated defenses.  Along with the EA1 and Sap S-layer proteins, other 
putative S-layer proteins have recently been found (61). These S-layer proteins are able to be 
recognized by the immune system as potential vaccine candidates (61). 
 
Surrounding the entire bacterium is the capsule, composed of polymers of poly-D-
glutamic acid (5, 154).  An amino-acid composed capsule is rare, but it has also found on the 
related species Bacillus licheniformis.  The two most important virulence factors are considered 
to be the capsule and toxins..  The capsule is encoded on the pX02 plasmid by the capB, capC, 
and capA genes.  The role of the capsule in pathogenesis is to interfere with phagocytosis of the 
bacterium and to surround the bacterium in a poorly immunogenic polymer to help hide the 
bacterium cell membranes from the immune system (5).  Both survival of the bacterium in the 
blood stream and progression to septicemia are also enhanced by the presence of the capsule.  
During germination and outgrowth in the presence of serum and elevated levels of CO2, the 
capsule is released through openings on the vegetative cell surface.  The formation of the capsule 
is exterior to the S-layer, but does not require the S-layer for its attachment to the cell surface (5, 
6, 7).  The capsule genes are essential for virulence in a mouse model of inhalational anthrax 
(119). 
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Other Virulence Factors 
 
 Bacillus anthracis encodes for a number of other virulence factors. Recently it has been 
found that if B. anthracis is grown under anaerobic conditions, it can induce production of the 
anthrolysins (62).  The anthrolysins consist of Anthrolysin O and three phospholipases C.  These 
four anthrolysins have overlapping function, but are essential for virulence in an inhalational 
model of anthrax in mice (35, 36).  Expression of the anthrolysins occurs in the early stages of 
infection, as they are turned on when the spores are engulfed by macrophages (62).  In fact, 
mutations in the phospholipases C lead to the inability of spores to grow in association within 
macrophages.  The hemolysin Anthrolysin O is secreted by vegetative cells and is lethal to 
human leukocytes, monocytes, and lymphocytes in vitro, in addition to lysing erythrocytes (148).  
Activity of Anthrolysin O is hindered by the presence of cholesterol, as minute quantities of 
cholesterol or sera leads to inactivation of the hemolysin (148). 
Bacillus cereus and Bacillus thuringiensis control a number of secreted hemolysins by 
the regulon PlcR (63).  The PlcR regulon in B. anthracis has been reported to be silent due to a 
plcR gene truncation (63).  But under strict anaerobic conditions the anthrolysins are active, 
suggesting that the truncated PlcR of B. anthracis is active under these conditions (62).   The 
PlcR regulon has been reported to inhibit sporulation and is incompatible with the AtxA-
controlled virulence regulon (64).  It was originally predicted to have been evolutionarily 
silenced due to this incompatibility (64).  All the anthrolysin determinants in B. anthracis have 
PlcR binding sites.  Transcription of plcR is activated during stationary phase in B. cereus and is 
autoregulated.   PlcR activates at least 15 genes encoding proteases, phospholipases, and two 
enterotoxin complexes (65, 63).   
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 Other virulence factors include the sortase genes, srtA and srtB, which play a role in the 
interaction of the vegetative bacterial cells and the macrophages. This role may be indirect, as 
the sortase mutants are not able to fully localize bacterial proteins to the exterior layers of the 
cells.  These mistranslocated proteins are likely the effector molecules that allow the bacterium 
to survive inside the host cells (37).  Bacillus anthracis also requires the presence of 
siderophores for growth in macrophages and for virulence, and like other pathogens, need this 
continual uptake of iron to be able to replicate efficiently enough to maintain an infection (38, 
46).  B. anthracis has two distinct siderophore gene clusters (38).   Due to the dramatic growth of 
B. anthracis in the host, it is understandable that anthracis would need siderophores to obtain 
sufficient iron at an optimal rate for maximal growth.  This increased growth is essential for 
virulence as the bacteria overruns the host immune system.  
 Two putative collagen binding adhesions have been identified and are expressed on the 
surface of B. anthracis vegetative cells (52).  These adhesions may help the bacterium bind to the 
extracellular matrix and help protect them from attack from the immune system.  The Gram-
positive cell surface is composed of many macromolecules, including peptidoglycan, techoic and 
lipotechoic acids (LTAs), S-layer, and cell surface proteins.  The teichoic and lipoteichoic acids 
give the bacterium an overall negative charge.  This negative charge on the teichoic acids 
becomes a major attractant for positively charged antibacterial compounds (93).   Many Gram-
positive organisms have developed the means of coating the negative charges on the LTA with 
D-alanine.  In B. anthracis this is accomplished by the products of the dltABCD operon.  dltA 
encodes a D-alanine:D-alanyl carrier protein ligase which covalently attaches D-alanine to the 4’ 
phosphopantetheine prosthetic group found on the D-alanyl carrier protein Dcp encoded by dltC 
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(93).  DltB is a transmembrane channel and DltD is a chaperone protein ensuring the fidelity of 
the D-alanine ligation to Dcp.   Loss of function of any of the four dlt genes is sufficient to 
terminate the entire pathway (93).  Addition of D-alanine to LTA in outgrown B. anthracis led to 
complete resistance to lysozyme and β-defensin-1 (produced by endothelial cells), and moderate 
resistance to sPLA2, HNP-1, and HNP-2 (defensins produced by phagocytic cells) (93).  
Addition of D-alanine to the LTA also allowed the vegetative cells to better survive engulfment 
by macrophages and afforded better resistance to positively-charged antibiotics (93).  
Staphylococcus aureus and Listeria monocytogenes strains lacking the dltABCD operon are less 
virulent in their respective mouse models (73, 90). 
   
 The exosporium of the endospore of B. anthracis contains an arginase (141).  Many 
bacterial pathogens are killed by efficient production of NO and other free radicals by 
macrophages.  The arginase in spores of B. anthracis can compete with the macrophage for 
arginine, inhibiting its ability to be modified into NO (141).   
 
Diseases 
 
     The symptoms and outcomes of persons infected with B. anthracis differ based upon 
the route of infection.  Spores gain entry into the body either thru open wounds in the skin, by 
ingestion, or by inhalation of the spores into the lungs.  Infection by all three routes can lead to 
serious and lethal systemic infection. 
 
 15
    One of the most common routes of infection in humans is entry of spores into abrasions 
in the skin. The incubation period ranges from 1-12 days. The cutaneous form is first 
characterized by the formation of a black pustule at the site of entry as the bacteria produces 
edema and lethal factors.  This painless eschar leads to significant edema of the surrounding 
areas, and in some cases the bacterium can gain access to the bloodstream, leading to systemic 
anthrax (29).  The mortality rate of cutaneous anthrax infections is about 20% without antibiotic 
treatment, but cases of progression to systemic anthrax can be up to 95% lethal.   
 
 The second route of infection, although fairly rare, is gastrointestinal anthrax.  This is 
usually caused by ingestion of undercooked meat from an infected animal, and this was last 
reported in the USA in Minnesota in 2000 (30).  The incubation period is 1-7 days.  Symptoms 
include bloody diaherria, severe abdominal pain, fever, and nausea.   This can be a common 
route of infection in herbivores, as the spores can be ingested along with associated plant matter.  
This is predicted to be the main lifecycle of B. anthracis, as some experts point out that B. 
anthracis probably does not maintain a full lifecycle in the soil.  In humans the mortality rate of 
ingestional anthrax is about 25-60%, even with appropriate antibiotic therapy (29). 
 
 The last, and by far the most lethal route of infection, is inhalational anthrax.  This is the 
most serious concern regarding anthrax, as an aerosolized attack using Bacillus spores could be 
potentially devastating if unleashed on a naïve population.  Disease is rarely recognized before 
bacteremia and toxemia develop.  It is difficult to diagnose, as it produces non-descript flu-like 
symptoms early in the course of infection. The Department of Defense estimates the LD50 in 
humans to be about 8-10,000 spores to cause infection, although that number varies greatly from 
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report to report. After a short time, the bacteria flood the bloodstream and the patient becomes 
septic, leading to shock, fever, and respiratory failure.  The patient usually succumbs within 24 
hours of the beginning of sepsis.  At this late stage the bacteria are very resistant to treatment, 
and the mortality rate is as high as 95% (29).  It is important that antibiotic therapy in cases of 
inhalational anthrax be continued for up to 60 days, as spores can persist in the lungs and cause 
repeat infection after the usual 14 day antibiotic therapy (167, 170). 
 
 Very rare reports of meningitis due to B. anthracis are usually a complication that arises 
from infection elsewhere in the body and dissemination after bacteremia and is extremely fatal 
(approaching 100%) (29).   Renal anthrax and ophthalmic anthrax have also been described, but 
are extremely rare. 
 
Treatment 
 
 Treatment of cutaneous anthrax is intramuscular administration of 1 million units of 
procaine penicillin every 12-24 hours for 5-7 days (26).  In serious illness, usually septic or 
pulmonary anthrax, 2 million units of penicillin G per day is administered intravenously or 
500,000 units administered intravenously through a slow drip every 4-6 hours.  Streptomycin, in 
conjunction with penicillin, has a synergistic effect in 1-2 g doses per day.  Some penicillin-
resistant strains of B. anthracis have been found (168).  Unfortunately, the strain used in the 
Amerithrax letters and in many historic outbreaks produces an inducible β-lactamase (169).   It 
appears to be highly sensitive in vitro, but in vivo in patients with high bacterial loads the 
bacteria may induce β-lactamase production and penicillin resistance.  There are published 
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reports of strains resistant to penicillin in vitro and in vivo (29).  Ciproflaxin at 400 mg 
intravenously twice daily is the new recommended treatment for those infected with anthrax 
(26).  The recommended regimen in inhalational anthrax is ciproflaxin plus 1-2 additional 
antibiotics (26).  The duration of treatment should be 60 days for inhalational anthrax, as 
ungerminated spores may germinate after prolonged stay in the lungs post-treatment and emerge 
into fatal infection (170).  
 
Disease Progression 
 
 Inhalational anthrax always initiates with the entry of spores into the pulmonary cavity.  
Soon after entry, the spores are taken up by resident alveolar macrophages and lung dendritic 
cells (LDCs) (39, 41, 42, 92, 116, 122, 134).  Alveolar macrophages consist of the major 
phagocytic population in the lungs, although LDCs are more efficient at phagocytosis of spores 
than alveolar macrophages.  Spores and germinated vegetative cells are able to be internalized by 
fibroblasts and epithelial cell lines in vitro as well (34).  Alveolar macrophages are the primary 
site of spore germination in vivo (22, 40, 41).  Spores germinate in the phagolysosome of the 
macrophages while in the lungs or en route to the mediastinal lymph nodes (39).  Germination 
within macrophages is dependent on the gerH germination operon and the presence of 
germinants L-alanine and adenosine found inside the macrophages (22).  There is little if any 
germination inside the lung mucosa itself (77).  Alveolar macrophages are thought to act as a 
“Trojan horse,” delivering the bacteria to the unsuspecting lymph nodes.  LDCs also sample lung 
environments and could potentially deliver the spores to the mediastinal lymph nodes as well.  
Both macrophages and LDCs express sporocidal activities in vitro (2, 28, 49, 92, 115, 122, 171).  
 18
There is roughly a 10-fold decrease in CFU of engulfed spores in the first 2.5 hours in vitro.  The 
roughly 10% that do persist begin to multiply and overtake the macrophages.  Macrophages play 
a critical role in the mouse model of infection, whereas PMNs play just a minor secondary role 
(124, 138).  A macrophage-deficient mouse model was more susceptible to infection, showing a 
role of the macrophage in resisting infection and not just as a “Trojan horse” (124).  
  
 Many spore and vegetative cell motifs are recognized by host pattern recognition 
receptors through MyD88-dependent and –independent processes.  Vegetative cells signal 
through TLR2, most likely due to the presence of lipotechoic and techoic acids in the cell wall, 
and Anthrolysin O signals through TLR4 (27).  NOD protein signaling, which recognizes 
bacterial peptidoglycan components, leads to upregulation of inflammatory cytokines and 
activation of macrophages.   Bacillus spp. have been found to be the most stimulatory of all 
bacteria tested in their ability to activate NOD1 (27).  Bacillus spp also activate NOD2, but these 
cell wall recognition receptors are not species specific (2).  NOD1 recognizes iE-DAP dipeptide 
and related structures found in all Gram-negative and some Gram-positive bacteria and NOD2 
recognizes muramyl dipeptide (MDP).  Most of the stimulatory activity of these receptors is 
found in the supernatant of growing cultures, suggesting that released modified pieces of 
peptidoglycan are the actual stimulants (2).   
 
Bacillus anthracis can induce an immunostimulatory response to both spores and 
vegetative cells during in vitro and in vivo infection.  Alveolar macrophages and LDCs coming 
into contact with spores produce TNFα, IL-1β, IL-6, and IL-8 (2, 28, 116).  The IL-1β response 
can be induced in vivo with as little as 100 spores (116).  IL-1β production leads to macrophage 
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expression of NO. The NO spore-killing response of macrophages is critically dependent on the 
internalization of spores, presumably due to internal recognition receptors (28, 141).  IL-1β and 
TNFα activate and recruit phagocytes, promoting clearance and destruction of ungerminated 
spores in the lungs (28).  Mouse strain susceptibility to B. anthracis spores was due to the 
presence of a gene locus involved in inflammation that leads to the production of IL-1β and IL-
18 (107, 175).  Spores themselves induce the production of IFN-β and activation of alveolar 
macrophages (2, 28, 116).  IL-6 induces B-cell antibody formation and recruitment (28, 116).  
Although many studies have shown the immunostimulatory effects of spores and vegetative cells 
of B. anthracis, in the context of host infection in a fully virulent strain, the host defenses begin 
to be shut down by the bacteria as soon as outgrowth and induction of virulence factor gene 
expression begins.    
 
Human dendritic cells exposed to B. anthracis spores have been shown to trigger 
reprogramming of their chemokine expression from the tissue homing receptors CCR2 and 
CCR5 to the lymph node receptor CCR7 (115).  This reprogramming would greatly help the 
spores by directing them to the regional lymph nodes and to their optimal destination more 
efficiently.  The engulfed spores germinate, multiply, escape the phagolysosome, and are 
released en route and during arrival of the macrophages and LDCs to the mediastinal lymph 
nodes (39, 49).  During this process B. anthracis upregulates and produces many of its virulence 
factors, including the toxins, capsule, and other virulence factors mentioned above.  PA and other 
toxin genes are produced in the germinating cells in as little as 1 hour after infection, 
concurrently with spore-laden macrophage arrival in the perivascular and peribronchiolar lymph 
node channels in a guinea pig model of infection (43, 114).  Lysis of the macrophages and the 
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release of the bacteria are dependent on an atxA-regulated gene that is not a toxin gene, but 
another gene product encoded on the pX01 plasmid (39).  The escape of the cells from the 
macrophages has also been linked to toxin secretion and InhA1 (140).   
 
At 4 hours post-infection in a guinea pig model spores and vegetative cells were found in 
and around phagocytes in the peristial lymph nodes (114).  In rhesus monkey and chimpanzee 
models of inhalation anthrax infectious spores were taken up and delivered to the mediastinal 
lymph nodes within 6-18 hours post-infection (114).  Once in the lymph nodes, the bacteria  
multiply rapidly and produce copious amounts of the toxins.  These toxins offset any 
immunostimulatory effects described earlier and lead to local immunosuppression within the 
infected lymph nodes.    
 
Initial immunosuppression by the B. anthracis toxins begins soon after germination of the 
spores in the alveolar macrophages and LDCs.  LT has been reported to abolish the secretion of 
proinflammatory cytokines by macrophages (118, 134) and LDCs (115, 120, 172).  LT can 
induce apoptosis of macrophages in vitro through the inhibition of p38 MAPK and its anti-
apoptotic signals (135, 138).  ET cooperates with LT in the suppression of early cytokine 
expression and inhibition of other phagocytic cell types.  The combination of ET and LT inhibits 
priming and activation of PMNs and their ability to produce sporocidal NO.  It also inhibits 
chemotaxis of PMNs to the lymph nodes and inhibits interferon production (139).  Exogenous 
interferon therapy blocks the apoptosis of macrophages, promotes activation, and leads to more 
effective spore killing (139).  LT disrupts the production of PLA2 in pulmonary phagocytes, 
which was found to be critical in anthrax spore killing (173).  After inhibition of PMNs and 
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alveolar macrophages, monocytes remain the sole defender left in the fight against B. anthracis, 
but to no avail, as LT inhibits the differentiation of monocytes into macrophages in vitro and 
therefore inhibits their ability to fight off invaders (174, 175).  Cholesterol-dependent anthrolysin 
O is lethal to human PMNs, monocytes, lymphocytes, and lytic to RBCs (148).       
 
             
Although the association of B. anthracis with antigen presenting cells such as alveolar 
macrophages and LDCs in the lymph nodes would suggest a potential for activation of an 
adaptive immune response, this is unlikely due to the short time course of infection owing to the 
rapid replication and toxin production by B. anthracis in inhalational cases.  In other forms of 
anthrax, the adaptive immune system may have time to be mobilized, but the adaptive immune 
response is also inhibited by the anthrax toxins.  LT has been shown to inhibit the expression of 
co-stimulatory molecules, which in the presence of bacterial antigen presentation may lead to not 
only the inability to mount a response to the antigens but likely the induction of tolerance (120).  
Tolerance to bacterial antigens may lead to the development of protective T regulatory cells to 
hinder future adaptive immune responses to B. anthracis epitopes and lead to a poor response to 
future infections. Additionally, LT and ET abolish T-cell activation and cytokine secretion 
including IL-2 induction of T-cell proliferation (177, 178). LT also acts as an inhibitor of the 
humoral response through action MKKs important in B-cell proliferation and IgM production 
(120, 137).  ET induces a Th2 shift and diverts the immune system into a poor anti-bacterial 
response (114, 176, 179).  Major players in the adaptive immune response are inhibited by the B. 
anthracis duo of toxins, and phagocytes are killed or deactivated leading to the unchecked 
proliferation of the bacteria in the lymph nodes. 
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 After a series of multiplications, immune cell death, and recruitment in the lymph nodes; 
the lymph node begins to swell. As the mediastinal lymph node expands, the bacteria soon gain 
access to the bloodstream and begin to stream out. The bacteria will also spread to adjacent 
lymph nodes through the lymphatics. Massive bacterimia ensues, followed shortly by toxemia as 
the cells secrete the toxins.  Some phagocytic cells have toxin-induced resistance to the 
circulating toxins, but the presence of the capsule protects the bacteria from the resistant 
macrophages and complement and is essential for dissemination throughout the body (119, 121).   
 
The last stage of the disease is characterized by the distant actions of the toxins at sites 
throughout the body, and usually begins at roughly 24 hours post-infection in a guinea pig 
model. The toxins lead to vascular injury with edema, hemorrhages, and thrombosis, through 
several mechanisms that lead to the death of the host.  LT acts on the major endothelial barrier 
by action on the central actin fibers and modification of endothelial cell distribution (112, 114, 
163, 182). LT’s actions on the VE-cadherins and induction of endothelial cell apoptosis induce 
bleeding, hypotension, and cardiac distress (123, 180, 181).  ET causes necrosis throughout the 
body in zebrafish, and rapidly kills mice (56, 112, 114, 183).  ET also leads to hypotension by 
action on cardiac pacemaker cells (112, 114, 183).  The two toxins’ attack on the circulatory 
system leads to hypotension, vascular collapse, and hypoxia throughout the body. The lack of 
adequate blood flow and hypoxia plus action of ET and LT leads to massive damage of the 
internal organs (136).  The PA subunit and Anthrolysin O activity together lead to hemolysis of 
the remaining RBCs (138).  LT and ET are linked to disruption of platelet function and 
aggregation, leading to worsening of the leakage in the blood vessels (182, 183).  The massive 
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vascular leakage leads to pleural effusion and this fluid buildup is usually the cause of death by 
asphyxiation. As the host dies and nutrients become limited the bacteria becomes dormant.  Once 
the bacilli become exposed to oxygen by opening of the remains by bloating gases, trauma, or 
autopsy, the bacilli quickly sporulate and can spread to the surrounding environment, starting the 
infection cycle anew.   
 
Disease in Animals 
 
Endemic anthrax cases usually begin by ingestion of food or water that is contaminated 
with anthrax spores. An animal dying of anthrax produces an enormous amount of spores, and 
when the carcass is exposed to air by escape of bloated gases the bacilli sporulate rapidly. The 
majority of outbreaks occur after heavy rains following a period of drought, as spores from the 
environment become distributed in the water.    
 
The disease in animals usually takes one of 3 forms: peracute, acute, and chronic. The 
peracute form is most often seen in cattle and other ruminants (26). Disease onset is rapid and 
death ensues quickly due to cerebral hypoxia.  The subacute and acute forms are frequent in 
cattle, horses, and sheep.   Symptoms of the subacture/acute phases consist of fever, a stop in 
rumination, periodic depression, respiratory difficulty, convulsions, and eventually death.  
Bloody discharges from the natural orifices as well as edemas in various parts of the body are 
sometimes observed (26). 
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Outbreaks in less susceptible species like pigs, and sometimes cattle, horses, and dogs are 
usually of the chronic form, although some animals will succumb to the acute form.  The main 
symptom of the chronic form is pharyngeal edema.  Frequently, a foamy bloody discharge can be 
seen coming from the sides of the mouth.  The animals die from asphyxiation.  The chronic form 
can also present itself as intestinal anthrax (26).  Under necropsy, the acute animals will display 
rapid decomposition and bloated carcasses.  Hemorrhaging and splenomegaly, as well as 
enlarged kidneys, liver, and lymph nodes are often seen.  The initial stage of every infection 
involves the spores gaining access into the body and germinating.   
 
Germination 
 
In order to initiate germination and restore vegetative growth when conditions favor 
outgrowth, the spore must be able to monitor the outside environment.  The germination 
receptors, located in the spore cytoplasmic membrane, encounter the germination signals as they 
pass through the external spore coat layer.  Early events in germination begin as the spore 
membrane increases in fluidity (184, 185).  Cations from the spore coat are released into the 
environment, including H+, K+, and Ca2+.  One of the major releases of cations is dipicolinic acid 
(DPA).  DPA release leads to degradation of the spore’s peptidoglycan cortex (17).  This is 
followed by release of Ca2+ ions and activation of lytic enzymes, like CwlJ and SleB.  These 
lytic enzymes start the degradation of the peptidoglycan and spore coat layers, leading to water 
uptake and the start of metabolism and increase in ATP synthesis (9, 11).  The SASPs (small 
acid soluble proteins) that coat and protect the spore DNA are degraded by germination proteases 
and any damaged DNA is repaired.  Degraded SASPs proteins are used as a nutrient source for 
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the emerging spore (8).    The current dogma is that different germinants bind to tricistronic 
encoded germination receptors on the inner membrane, like the well characterized GerA receptor 
of B. subtilis (16).   
 
The GerA family of germination receptors react to different stimuli (21). High 
concentrations of alanine (100 mM), or low concentrations (1 mM) with the presence of His, Pro, 
Trp, or Tyr can induce significant germination in 1 hour (16).  D-alanine can inhibit germination 
by L-alanine (187).  The GerS germinant receptor family recognizes aromatic ring structures.  
The presence of purines (inosine, adenosine, or guanosine [weaker]) with many amino acids (A, 
C, H, M, F, P, S, W, Y, V) can induce germination (16).  This induction was inhibited in the gerS 
mutant spores, which were unreactive to inosine and alanine-induced germinants (16).  No 
purine alone will cause germination in B. anthracis, but can in B. cereus (186).     
 
GerX, another of the GerA family of receptors, is located on the pX01 plasmid of B. 
anthracis.  gerX mutants are attenuated for virulence in a mouse model (41).  GerH also plays a 
role in germination of endospores in macrophages in vitro (22).  Different Bacillus species react 
to differing germination stimuli (11).  B. cereus and B. anthracis germinate most efficiently in 
the presence of alanine or inosine and cofactors.  The presence of other cofactors greatly 
increases the ability of the germination receptors to signal.  Anti-spore polyclonal antibodies 
significantly hinder the ability of spores of B. anthracis to germinate, potentially by blockage of 
access of germinates to germination receptors or by blocking lytic digestion of the spore coat 
layers (20).   
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Vaccination 
 
Anthrax was the first disease in which the principle of bacterial vaccination was found to 
be effective. 1881, in Pouilly Le Fort, the Pasteur strain of B. anthracis was the first attenuated 
bacterium used successfully as a vaccine.  In 1937 the Sterne strain of B. anthracis was isolated.  
It is cured of the pX02 plasmid, rendering it unable to produce the antiphagocytic capsule.  The 
Sterne strain is used as a live vaccine to this day, but only in a veterinary capacity.  It induces 
great protection in many studies and is utilized as a livestock vaccine in anthrax-endemic regions 
(30, 105). Since it is a live vaccine and has potential to harm the animal with its other virulence 
factors, it has not been considered safe for use on humans.  However, it was utilized as a human 
vaccine during the cold war years in the former Soviet Union.  Several new vaccine candidates 
have been proposed and/or tried in animals over the last half-decade. 
   
Human vaccines based on cell-free filtrates of nonencapsulated strains of B. anthracis 
were developed in several Western countries in the 1950s. PA and other secreted proteins were 
absorbed from cell supernatants using aluminum hydroxide gel (Alum), and this cell-free 
cocktail was given to humans.  This newer vaccine, name AVA for Anthrax Vaccine Adsorbed 
requires doses at 0, 2, and 4 weeks as well as at 6, 12, and 18 months, followed by annual 
boosters.  Annual booster shots are necessary, as the vaccine is only protective for roughly a year 
(105). The vaccine confers poor protection from challenge with aerosolized spores in a number 
of animal models (106, 108).  AVA vaccines also provide less protection than the live spore 
Sterne strain vaccine and have a number of side effects (105, 189).  Reaction to the AVA vaccine 
is not just to PA, although it is the major factor responsible for protection. Approximately 69 
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proteins of B. anthracis react to antiserum generated by the AVA vaccine, which may not 
constitute the full gambit of protective antigens (31, 104).  Full protection against anthrax 
infections may require the use of multiple immunogens.   
 
A laboratory study has shown that inclusion of formaldehyde-inactivated spores to AVA 
or other PA-based vaccines results in total protection in both mice and guinea pigs (3).  Even the 
newer recombinant PA-based vaccines provide less protection than the live Sterne spore 
vaccines, but have fewer side effects than AVA (30).  The addition of better adjuvants to the 
AVA vaccine has been show to increase its efficacy (101). A recombinant PA vaccine bound to 
alhydrogel has been found to protect rhesus monkeys from an aerosolized dose of virulent B. 
anthracis spores (98). Production of antibodies by other more efficient vaccine delivery methods 
may also be helpful in future vaccine strategies (102).   
  
Ideally a vaccine could be developed necessitating fewer doses and conferring better 
protection than the currently used AVA vaccine, and with the potency of the Sterne vaccine 
without the hazards. PA is the basis for many of the new vaccine designs.  Other immunogens, 
for instance the capsule (103), could be beneficial additions to the AVA or other recombinant PA 
vaccine strategies.  Antibodies to PA offer protection by neutralization of the LT and ET toxins 
(98).  High-affinity monoclonal antibodies produced against PA protect animals during B. 
anthracis infections (100).  Laboratory animals used in the development of vaccines include 
mice, guinea pigs, and rabbits, with the use of rhesus monkeys as a non-human primate model.  
Mice are very susceptible to anthrax, with the presence of only either the capsule or the toxins 
being necessary to produce lethal infections (107).   
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      Production of anti-spore antibodies and anti-spore IgG inhibits the germination of B. 
anthracis.  Antibodies against both germinated and ungerminated spores have the same 
neutralizing effect (20).  Anti-PA antibodies have the ability to stimulate phagocytosis of spores 
by macrophages and inhibit some spore germination in vitro (43).  The ability of anti-spore 
antibodies to inhibit germination is not a consequence of overall binding, but correlates to which 
epitopes are bound.  There is no association between agglutination and abililty to inhibit 
germination (20).  One proposed mode of action is the blocking of the pores that allow 
germinants to enter the spore by the anti-spore antibodies (20).  GerH is necessary for the 
germination of spores in macrophages (22).  The use of gerH mutant spores may allow the use of 
a spore vaccine to illicit an anti-spore response without the fear of germination and infection.  
Some protection afforded by spore vaccines is accomplished by stimulation of IFNγ producing 
CD4+ T lymphocytes (197).  
  
 The addition of BclA, a potent immunogen in the exosporium of the spore, to a 
recombinant PA DNA vaccine leads to better protection than PA alone (53).  Other spore 
antigens may increase the protection as well.  Antibodies to recombinant PA lead to delayed 
germination of spore and a modest increase in uptake by macrophages and spore killing.  (43)  
The tetrasaccharide of the BclA glycoprotein may also be an effective vaccine addition that can 
illicit a response and be added to future vaccines (82). 
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Sporulation 
 
Most of the known literature on sporulation has been derived from studies of  B. subtilis.  
Bacillus subtilis is genetically best characterized member of the genus Bacillus.   Sporulation of 
B. anthracis has not been studied in detail and general extrapolations can be dangerous, as B. 
anthracis has over 1000 genes with no known homology to B. subtilis. B. anthracis also contains 
an extra spore layer (the exosporium) and some homologs of B. subtilis sporulation genes have 
been shown to play different roles in B. anthracis. 
 
Under conditions of nutrient starvation and in the presence of oxygen, cells of the 
Bacillus spp. undergo the process of sporulation.  Sporulation allows production of a dormant 
spore which can survive adverse conditions and allow the bacteria to reemerge when the 
environment is more suitable to sustained growth.  The production of endospores allows Bacillus 
spp. to become resistant to UV rays, ionizing radiation, pressure, heat, desiccation, high salinity 
levels, pH, and chemical agents.  This dormant and highly resistant endospore allows the 
survival of the bacteria in contaminated soil for many years.  Many researchers have argued that 
B. anthracis does not grow in the soil and persists only as endospores.  The presence of nitrate in 
the soil leads to sporulation and killing of any vegetative cells (4).  In a more recent study, B. 
anthracis spores were found to germinate and multiply in the rhizospheres of several grass 
species (68). The centrally located spore has virtually no detectable levels of metabolism, little to 
no ATP and NADH, and no enzyme activity (192).  Cells remain in this metabolically inactive 
form until the presence of inosine and/or alanine and co-factors leads to initiation of germination 
and outgrowth.   
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 During the process of sporulation, groups of genes are sequentially activated and silenced 
in an 8-10 hour period that leads the nutrient-deprived cell through a series of developmental 
stages (110).  This process is broken down into a series of time points denoted using the Roman 
numerals 0-VII (47).  Each Roman numeral signifies the hour in which the events each event 
occurs.  Gene mutations which are essential at each timepoint are denoted by the addition of the 
respective Roman numeral and order that they are important, i.e., the sporulation mutant Spo0A 
is active during the 0 hour time point (end of exponential growth).Sporulation is initiated at 
Stage 0 with the master sporulation regulator Spo0A.  During Stage I DNA replication initiates at 
an axial filament in the center of the vegetative cell.   Stage II denotes the time point where the 
spore septum begins to be formed to initiate the unequal cell division and formation of two 
compartments, the larger mother cell compartment and the much smaller forespore compartment.   
 
The forespore is engulfed by the mother cell membrane, leading to the forespore being 
encased by two bilipid membranes. This is the hallmark of the third stage of sporulation (Stage 
III).  During Stage IV, a thick layer of carbohydrate and spore-specific peptidoglycan is layered 
between the two forespore membranes.  This layer is known as the cortex.   The outer membrane 
of the forespore is layered with sequential layers of spore coat proteins and calcium dipliconate 
during Stage V of sporulation.  Addition of the final spore coat layers, which provide several of 
the inherent resistance properties that protect the endospores, and the final exosporium formation 
are accomplished during Stage VI.  The outermost exosporium layer is synthesized during Stage 
VI in Bacillus anthracis, cereus, and thuringiensis (18, 191).  The final stage of sporulation, 
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Stage VII, is marked by the lysis of the mother cell and release of the mature spore into the 
environment (47). Figure 2 outlines the general process.   
 
Sporulation gene transcription in B. anthracis has been found to occur in 5 semi-distinct 
waves (54, 88).  Interestingly, the spore associated proteins are produced much earlier than they 
are incorporated, and these proteins are predicted to be inherently more stable than their 
vegetative cell counterparts, leading to increased concentration of spore related proteins and a 
decrease in shorter lived vegetative cell proteins (54, 88). Sporulation-specific sigma factors are 
transcribed in a defined series that has been well characterized in B. subtilis, and in part attribute 
to the waves of sporulation gene transcription (146). 
 
Regulation of Sporulation and Sigma factors 
 
Regulation of gene expression in bacteria occurs primarily at the level of transcription.  
DNA-binding proteins can significantly affect the efficiency of transcription, but the specificity 
of the transcription reaction depends on the interactions between the RNA polymerase (RNAP) 
and the DNA promoter sites with which they recognize.  RNAP is most commonly found in two 
parts, the core RNAP, which catalyzes the polymerization of ribonucleotides into a RNA 
complementary copy of a DNA template, and the holoenzyme complex, which contains subunits 
of the RNAP core complex (β, β’, and two α) plus an additional protein subunit called the sigma 
factor.  The sigma factor determines the specificity of the RNAP for target gene promoters and 
dissociates from the core RNAP when transcription from the sigma-specific promoter is initiated. 
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During the life cycle of a bacterium, it shuffles different sigma factors to modify its gene 
expression to best suit its current environment and various stresses. Bacillus subtilis has had its 
cascade of sigma factors well characterized.  Alternative sigma factor usage in B. subtilis can be 
used as a model for alternate sigma usage in B. anthracis, but some care must be taken, as 
sporulation target genes and recognition sequences are not identical between the two species.   
 
Sigma A is the primary sigma factor in the vegetative cell.  It is responsible for 
transcription of the housekeeping genes and genes involved in very early sporulation.  It is by far 
the most abundantly utilized sigma factor, involved in expression of most genes utilized during 
growth in rich media (110).  The σA-dependent transcripts include DNA damage response genes, 
heat shock response genes, genes responsible for stationary phase degradative enzyme synthesis, 
and the development of bacterial competence. The sigma factor σA is critical for the initiation of 
sporulation and directs the transcription of several of the spo0 genes, most notably Spo0A. 
Spo0A is a DNA binding protein that acts as the transcriptional activator/repressor that initiates a 
cascade of events leading to sporulation. σA has been found to be act on sporulation-related 
genes through at least Stage II of sporulation (activation of SpoIIG and SpoIIE; 110). 
 
The sigma factor σB regulates the expression of stress responses, including responses to 
heat shock, O2 limitation, and exposure to high salt or ethanol (110).  It is also activated when 
Bacillus enters into the stationary phase of growth.  Although σB plays a role in the response to 
these stresses, it is not essential, as a σB-null mutant is not more susceptible to environmental 
stressors (110).   σB plays no significant role in transcription of sporulation related genes.   
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The extremely low abundance of σC has limited its study, and it has no major effects of 
regulation of transcription of genes to date (110).  σD is involved in flagellar gene expression, 
secretion machinery, and chemotactic protein sensors (110, 113).  Both σC and σD play no major 
roles in sporulation, despite σD’s upregulation during the exponential and stationary phase of 
growth.  σL likewise does not play a role in sporulation, with just a minor role in expression of 
amino acid degradative enzymes (110, 113). 
 
σH expression is controlled by early stage sporulation factors.  σH is essential for 
sporulation, but it is also present during exponential growth where it may play a role in 
transcription of vegetative genes (110, 113). Most sporulation gene transcripts are also enhanced 
by the activity of Spo0A related enhancers of transcription.  σH also plays roles in competence, 
TCA cycle enzyme synthesis, and DNA repair enzymes (110).  σH has been recently found to be 
involved in toxin gene expression in B. anthracis (113). 
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Figure 2.   Top panel denotes a representation of the sporulation cycle of B. subtilis.  The bottom 
panel demonstrates the interactions between sporulation specific sigma factors, with direct 
effects denoted by black arrows and indirect effects denoted by blue arrows.  Adapted from 
Hilbert et al. (111) 
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Both σE and σK are mother cell-specific transcription factors. They direct early and late 
phase transcription of genes, respectively, and transcribe genes essential to addition of spore coat 
and exosporium proteins.  The σE sigma factor becomes active during Stage II of sporulation and 
into later stages.  Seventeen known genes in B. subtilis are under the regulation of the σE (110, 
113).  σE-dependent transcripts are responsible for spore septum formation, forespore 
engulfment, peptidoglycan and cortex formation, and layering of some of the early spore coat 
proteins, including CotE.  σE-dependent products are also involved in the cleavage of pro-σK into 
active σK (110).  This cleavage is tightly regulated, and delays production of active σK until its 
products are ready to be assembled into the spore over the initial layering of the σE transcribed 
products.  σK expression initiates between the third and fourth stage of sporulation, and the pro-
σK is cleaved to its active form during late stage IV.  This may rely on processing by a protein 
that is dependent on σG expression in the forespore (110, 113).  σK-controlled genes include 
germination receptors, genes involved in DPA accumulation and synthesis, and most of the 
genes that encode proteins in the spore coat and exosporium.  σK, by virtue of its replacement of 
other sigma factors, also acts to inhibit production of early stage sporulation genes (111).   
 
The sporulation genes that are transcribed in the forespore compartment utilize σF- and 
σG-specific promoters.  SigF is transcribed during stage II of growth.  σF activation in the 
forespore compartment is due to cleavage of the pro-σF into the active form (110). σF is activated 
after production of the spore septum between the mother cell and the forespore. σF transcribed 
genes include those encoding the enzymes and other products necessary for protein cleavage and 
efficient nutrient acquisition in the germinating spores.  σF also plays a role in the cleavage of the 
 36
pro-σE protein into its active form by an unknown mechanism.  σG is a forespore specific sigma 
factor.  It is active during the third and fourth stages of sporulation. σG transcribed genes include 
those encoding the SASP proteins, which are involved in protection and packaging of the spore 
DNA. A σG-encoded protein acts by an unknown mechanism to cleave pro-σK into σK (111). 
These sporulation-specific sigma factors are sequentially linked and act upon one another to 
precisely regulate the assembly of the spore in different compartments in a phase-dependent 
manner (109). This ensures an ordered, complete structure is constructed, leading to the ability of 
the spore to survive many environmental challenges. The interactions between the spore-specific 
sigma factors are demonstrated in Figure 2.  Table 1 summarizes the sigma factors expressed in 
B. subtilis, their roles, and their putative binding sites.      
 
Promoters
Sigma Factor Genes       Function -35 Spacer -10
Vegetative Sigmas
σA sigA, rpoD Housekeeping/early sporulation TTGACA 17 TATAAT
σΒ sigB General stress response RGGXTTRA 14 GGGTAT
σC Unknown Postexponential gene expression AAATC 15 TAXTGYTTZTA
σD sigD, flaB Chemotaxis/flagellar gene expression TAAA 15 GCCGATAT
σH sigH, spoOH Postexponential gene expression, RWAGGAXXT 14 HGAAT
Competence and early sporulation
σL sigL Degradative enzyme gene expression TGGCAC 5 TTGCANNN
Sporulation Sigmas
σE sigE, spoIIGB Early mother cell gene expression ZHATAXX 14 CATACAHT
σF sigF, spoIIAC Early forespore gene expression GCATR 15 GGHRARHTX
σG sigG, spoIIIG Late forespore gene expression GHATR 18 CATXHTA
σK sigK, spoIVCB:spoIIIC Late mother cell gene expression AC 17 CATANNNTA
Table 1:  Summary table of sigma factor target genes, sequences, and role in sporulation.   H=A 
or C, N= A,G,T,or C, R=A or G, W=A, G, or C, X= A or T, Y=C or T, and Z= A or G. Adapted 
from Haldenwang et al. 1995 (110) 
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Spore Structures 
 
The spore is the infectious agent of B. anthracis.  The B. anthracis endospore is formed 
in several steps.  Assymetric septation of the nutrient-starved vegetative cell produces the large 
mother cell and small forespore compartments.  The mother cell then engulfs the forespore, 
encasing it with two distinct membranes.  The first step in assembly of the spore is the packaging 
of the DNA, ribosomes, tRNAs, and other cellular components into the core of the forespore.  
Newly-packaged DNA and enzymes are protected by the production of the thick layer of 
modified spore-specific peptidoglycan, called the spore cortex, between the two forespore 
membranes (11).  DNA is condensed by small acid soluble proteins (SASPs), low molecular 
weight proteins that surround the DNA and protect them from UV, radiation, heat, and other 
chemicals (58).  SASPs are synthesized late in sporulation.  They bind and alter the DNA 
structure and properties dramatically.  The low water content of the core inactivates the enzymes 
present in the core and helps induce dormancy.   
 
This low percentage of water in the core (27-55% in spore versus 75-80% in growing 
cells) and the low amount of free water in the core restricts the flow of macromolecules and 
enhances the resistance properties of the spore due to freezing and desiccation.  Also in great 
abundance in the spore core is pyridine-2,6-dipicolinic acid (DPA).  DPA consists of 5-15% of 
the spore dry weight and is chelated mostly by Ca2+.  This molecule is secreted in the first 
moments of spore germination in conjunction with the influx of large amounts of water. DPA 
plays a large role in the reduction of the water content of the spore core (58). 
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External to the cortex is found a series of proteins that form a lattice called the spore coat.  
The spore coat is made up of proteins synthesized in the mother cell and layered onto the 
outermost of the two forespore membranes.  The spore coat consists of greater than 50 proteins 
in B. subtilis (10).  Surrounding the spore coat, and presumably the last layer placed on the 
outside of the spore, is the loose balloon-like structure known as the exosporium.  The 
exosporium is also synthesized within the mother cell. After a final stage of maturation the 
mother cell lyses to release the mature spore.   See Figure 3. 
 
exosporium
basal layer
spore coat
cortex
exosporium nap
(BclA)
B. anthracis spore
 
Figure 3: Layers of the B. anthracis spore 
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The Spore Coat 
 
In the well characterized B. subtilis, the spore coat contains a complex mixture of at least 
24 proteins which can be resolved into two or three morphological layers (55, 87).  Coat 
assembly requires regulatory proteins and key morphogeneic factors.  The coat also plays a role 
in germination, perhaps by providing access for germinants to the germinant receptor proteins 
located in the cytoplasmic membrane (24).  Lytic peptidoglycan hydrolase enzymes may also be 
located in the spore coat, which are involved in lysis of the spore cortex during germination 
(188).  The spore coat proteins undergo extensive crosslinking, with many of the spore coat 
proteins containing multiple cysteine residues.  The crosslinked spore coat is involved in some 
spore resistances: like exogenous lytic enzymes that can degrade the spore cortex, UV light, 
hydrogen peroxide,  and can protect the spore from predation from protozoa, but has little to no 
role in spore resistance to heat, radiation, and other chemicals (58, 158).   
 
Although B. anthracis and B. subtilis have similar numbers of predicted spore coat 
proteins and a few common coat proteins, the outer coat layers vary significantly (55).  The B. 
subtilis spore coat is a relatively thick structure with a distinctly light inner layer and a darker 
outer layer (87).  In contrast, the B. anthracis spore coat,appears thin and compact (87).  It is also 
separated by a gap, sometimes called an interspace, from the exosporium, not present in B. 
subtilis.  In most cases, the precise function of various spore coat proteins has been difficult to 
determine, since gene disruptions had no measurable phenotypic effects.  
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 Coat assembly in B. subtilis is a complex multistep process.  One early event in coat 
assembly is the essential localization of SpoIVA to the outer membrane of the forespore on the 
mother cell side (110, 113).  SpoIVA marks the exterior of the outer membrane as the site of all 
future coat protein assembly and directs the layering of the initial spore coat layers.  A layer of 
coat proteins are assembled around SpoIVA. A spoIVA mutant in B. anthracis failed to progress 
past the early stages of sporulation and never produced mature spores (87).  These mutant spores 
lacked the cortex, and the mother cells were filled with swirls of electron dense coat material 
(87).  SpoIVA appears to have a role in B. anthracis similar to that in B. subtilis, namely marking 
and directing assembly of the spore coat layers on the outside of the forespore.  The outermost 
part of the initial coat layer contains the coat protein CotE (87). In the final stage of coat 
assembly, the inner and outer coat layer appears between the CotE and the SpoIVA layers (87).  
The CotH protein, directed by the CotE protein in B. subtilis, directs deposition of several other 
coat proteins. 
   
 The B. anthracis cotE mutant was found to lack attachment of the exosporium, and also 
had detached spore coat layers (87).  Examination of the cotE mutant spores under AFM 
revealed a loss of the typical pole to pole ridges found in B. anthracis spores (12).  These data 
show that the CotE protein is essential for anchoring the coat layers and exosporium to the core 
and that it also plays a role in the proper construction of the spore coat.  Proteomic studies did 
not find CotE in the exosporium, so its role in anchoring of the exosporium occurs within the 
spore coat, or it plays an indirect role (87).  CotE may play a role in stability of the exosporium, 
as it may control ExsY and CotY assembly, since these genes are homologs of the CotZ protein 
of B. subtilis, which is controlled by CotE (87). 
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The ExsA proteins of B. cereus and B. anthracis have been found to be vital in proper 
assembly of the spore coat and the exosporium (81).  Obvious defects in the spores were evident 
under transmission electron microscopy (TEM).  Mutant spores became extremely sensitive to 
lysozyme, were unstable, and tended to lyse when subjected to freezing and thawing.   The spore 
coat layers and exosporium were misformed, and remained free and unattached to the spore core 
(81). 
  
A cotY mutation in conjunction with an exsY mutation leads to spore coats that are very 
thin, with a decrease in resistance to lysozyme, phenol, chloroform, and toluene (86).  The 
double mutant has difficulty constructing an exosporium, and CotY as well as CotE may play a 
role in maintaining an ordered structure upon which an exosporium can be constructed (86, 87). 
 
A major coat protein has been identified in all of the B. cereus family members, and it 
has been named CotA.  This 13 kDa protein has 6 cysteine residues and is likely to crosslink 
with many other coat proteins (24).  CotA confers resistance to lysozyme.  The cotA determinant 
has a consensus σK promoter element, consistent with the appearance of the CotA antigen at 
stage IV of sporulation.  TEM studies reveled that a cotA mutant lacked the majority of the spore 
coat as well as had an increased sensitivity to chloroform, phenol, and bleach.   AFM studies 
show the coat of B. anthracis and B. cereus spores are covered in ridges that run along the long 
axis of the spore, and that presence of the exosporium hides these features (12).  These ridges 
may be reflective of the dehydration state of the spore core at the time of imaging (14). 
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Exosporium 
 
       The outermost layer of the B. anthracis spores is the exosporium.  Bacillus subtilis, the best 
characterized spore-former, does not possess a defined exosporium, consequently, many of the 
mechanisms involved in its construction are unknown and currently under investigation. 
Scanning electron microscopy has revealed the exosporium contains a paracrystalline basal layer 
and a hair-like outer layer called the nap (142, 143). Several proteins of the exosporium are 
related to the morphogenetic and outer spore coat proteins of B. subtilis, but many of them have 
no known homology to any known proteins outside the B. cereus family.  A proteomic analysis 
of exosporium proteins revealed the presence of 137 exosporium-predicted proteins, but the 
extract used in this study was not pure exosporium, and contained contaminating spore coat and 
other proteins (88).   
 
The primary permeability barrier and source of spore antigens is the exosporium (15, 23).  
The exosporium may also play a role in interactions with the soil environment, binding to 
immune cells in the mammalian host, and evasion of host defenses. It helps protect underlying 
epitopes from recognition by the innate immune system and also allows the spores to be more 
resistant to killing by host macrophages in vitro (28, 39).  This exosporium layer is chemically 
complex; consisting of protein, amino and neutral polysaccarhides, and lipids (190). Exosporium 
antigens first show up at stage III of sporulation.  The exosporium has been speculated to be the 
reason for the extreme hydrophobicity of the spore, and therefore might play a role in adhesion 
(78).   
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 Exosporium Gene Expression
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Figure 4:  Expression of late sporulation genes, adapted from Bergman et al. (54) 
 
 Characterization of exosporium proteins extracted from B. cereus has recently identified 
more than 10 proteins (79).  These included ExsB, ExsC (not expressed in anthracis), ExsD, 
ExsE, BxpB/ExsF, ExsG and ExsJ. Only the exsJ and bxpB genes have been further 
characterized to date.  ExsJ is a glycoprotein that migrates at a mass of 72 kDa and 205 kDa.  
This most likely represents the monomer and trimer versions of the protein, as is found in the 
similar BclA and BclB proteins of B. anthracis (79).  The exsJ gene has high homology (>88%) 
to the exsH gene found elsewhere in the chromosome, and the major differences between the two 
proteins are found in the N-terminal regions of the two proteins.  In both B. anthracis and B. 
cereus, the presence of an exosporium operon is apparent.  Following the bclA determinant is a 
series of glycosylation biosynthesis genes (glycosyltransferases and methyltransferases) followed 
by a rhamnose gene cluster. The spore carbohydrate glycosylation machinery is predicted to 
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place the sugar residues on the BclA and BclB proteins. The glycosylation machinery 
determinants are transcribed concurrently with bclB, bclA, and other σK-directed genes, 
consistent with late sporulation mother cell expression.  Beyond the rhamnose determinants is a 
series of genes that sequence similar to B. subtilis coat genes.  Among this group of genes is the 
gene encoding the basal layer protein BxpB/ExsF, ExsY (a CotY homolog), and CotY proteins.  
This region is conserved among the B. cereus family members, but only parts of the operon are 
present in the B. subtilis chromosome (79). See Figure 5. 
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Figure 5.  The bclA operon and adjacent spore-associated operons. 
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Several proteins have been isolated from the exosporium of B. anthracis.  Alanine 
racemase and nucleoside hydrolase were isolated and identified, as well as the CotY and ExsY 
components (13).  S-layer proteins were also found, but these are likely a contaminant (13).  The 
BxpB protein was identified in the B. anthracis exosporium (13).  BxpB/ExsF, ExsY, and BclA 
were all found in a high molecular weight grouping of proteins migrating at greater than 250 kDa 
(13).  A novel new protein, ExsK, was also found in the B. anthracis exosporium, but has not 
been identified as an exosporium protein yet in B. cereus (13).  The B. anthracis exosporium 
contains an arginase which maycompete with macrophages for free arginine, limiting their 
ability to produce NO and other free radicals to attack the germinating cells (141). 
 
Very little is known about the basal layer and its associated proteins.  The basal layer 
consists of four paracrystalline sheets, each exhibiting a hexagonal perforate lattice structure 
(142, 143, 159).  The basal layer is comprised of many proteins, including BxpB (25).  BxpB, 
along with BxpA, BxpC, and ExsK; are all currently predicted to be basal layer proteins (25).  
The bxpB determinant encodes a 17 kDa protein found to be located in the basal layer by 
immunogold labeling.  This protein forms strong covalent complexes with BclA and other basal 
layer/nap proteins, including ExsY and CotY.  ExsY and CotY are homologues of CotZ, which 
are CotE-controlled spore coat proteins of B. subtilis (87). 
 
  When BxpB is SDS-extracted from spores, it is isolated as both a monomer and in high 
molecular weight complexes with BclA and possibly ExsY and CotY.  bxpB mutants cannot 
assemble a hairlike nap, although BclA is still synthesized at normal levels (25).  The lack of 
BxpB leads to expedited spore germination and outgrowth, potentially due to easy access of 
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germinants into the spore (25).  CotY, ExsY, CotB-1, and CotB-2 may be associated with the 
basal layer or outer coat protein layers (25).  Also incorporated into either the basal layer or the 
nap is alanine racemase, superoxide dismutase, and inosine-uridine-preferring nucleoside 
hydrolase.  These enzymes could protect the spore from reactive oxygen species during 
infection, and suppress premature germination by less than optimal levels of germinants (13, 79, 
187).  The major germinants of B. cereus spores are alanine and inosine (9, 11, 16).  Alanine 
racemase converts L-alanine to D-alanine, a competitive inhibitor of germination. A nucleoside 
hydrolase would degrade inosine, preventing germination by minute quantities of inosine. 
   
 The immune inhibitor A protein (InhA) protein has been found in all three species of the 
B. cereus family in various degraded and native forms (18). This protein, best characterized in B. 
thuringiensis, is a zinc metalloprotease and degrades proteins of the immune system (18).  It is 
highly toxic to Drosophila.  It migrates as a band of about 72 kDa and as several smaller bands of 
46, 22, and 18 kDa (18).  The protein is secreted throughout the life cycle of the vegetative cell, 
but a homolog is found associated with, or is a contaminant of, exosporium preparations.  InhA 
is a major component of the exosporium of B. cereus and B. thuringiensis, but is only found in 
minor quantities in B. anthracis (13, 79, 140).  The InhA metalloprotease allows B. cereus spores 
to escape from macrophages and may play a small role in macrophage escape by B. anthracis as 
well (140). 
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Formation 
 
Exosporium antigens appear as early as stage III of sporulation (191).  B. cereus, B. 
anthracis, and B. thuringiensis all contain specific glycoproteins on the surface layer of the 
exosporium (18, 99, 19).  The major glycoprotein in B. anthracis is BclA which is highly 
immunogenic (19).  It is the major component of the hair-like nap that forms the outermost layer 
of the exosporium. Many proteins of the exosporium have recently been described, but the 
overall function of the exosporium has yet to be determined (13). This loose balloon-like 
structure is made up of at least 20 proteins (13, 18, 79).  Most of this layer is made up of protein, 
but many of these proteins are glycosylated and potentially lipidated.  The exosporium can bind 
to lectins, which may bind to the many glycosylated proteins found in the exosporium (193).  
The exosporium is 2% of the mass of the spore and is about 50% protein, 20% lipid, 20% neutral 
polysaccharides, and 10% other components (190).  
 
The BxpA and BxpB/ExsF proteins have been isolated from the exosporium (15).  The 
Gln-rich BxpA protein is predicted to form sheaths, as it shares homology with filarial sheath 
proteins (15).  A bclA mutant allows antibody access to basal layer proteins, suggesting the BclA 
protein inhibits the ability of antibodies to access the basal layer.  The sugarless rmlD mutant, 
responsible for glycosylation of BclA, also allows access of antibodies to the basal layer.   This 
suggests the glycosylation of BclA leads to inhibition of antibody entry (15).  Anti-BxpA 
antibodies bind BxpA more efficiently in the glycosylation-deficient ∆bclA and ∆rmlD strains 
(84). The BxpB protein does not contain a repeat region and is associated with BclA and other 
high molecular weight exosporium proteins.  The exsFA and exsFB map to different parts of the 
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B. anthracis chromosome, but are homologs of each other, sharing 78% identity with the 
majority of the differences occurring at the N-termini of their protein products.  The basal layer 
proteins ExsFA and ExsFB (BxpB and homolog) proteins are also involved in exosporium 
integrity and the incorporation of BclA into the nap (80).  Loss of ExsFA leads to a decrease in 
BclA incorporation in the nap, and a double knockout of ExsFA and ExsFB leads to no 
incorporation of BclA in the nap (80).  ExsFA and ExsFB are found in high molecular weight 
complexes co-migrating with BclA, BxpB, ExsY, and CotY (80).     
 
Nap 
 
A major component of the exosporium is the hair-like nap, which is mostly comprised of 
BclA (15, 19).  The nap and the associated hair-like filaments were first described on the 
exosporium of B. anthracis in 1966 (144).  Truncations of the BclA CLR also lead to a decrease 
in the size of the hair-like filaments on the outer surface of the spore; further evidence that this 
protein is BclA (75, 83).  Proteins of the nap are likely to be the first proteins seen by the innate 
immune system in interactions with the spores (83, 19). The hair-like nap differs in length from 
species to species, and even from strain to strain (15, 83).  The nap does not play a role in the 
resistance of the spore to various insults (19).    
 
BclA also comprises the major species seen on blots on an exosporium extraction when 
using a polyclonal anti-spore antibody (15, 19).  Antibodies both to the BclA protein or the 
carbohydrate portion of BclA can be produced (15). Ruthenium red allows the visualization of 
the nap under TEM by binding to the glycoprotein moities (156). A 715 Da tetrasaccharide and a 
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324 Da disaccharide are linked to BclA by GalNAC (19, 23). Many copies of the tetrasaccharide 
are linked to the collagen-like region of BclA, but the disaccharide most likely is attached 
outside the collagen-like region (CLR) (23).  The nap extends from the exosporium for 600Ao 
(15, 83).  Deletions in the CLR lead to a decrease in the glycosylation with the tetrasaccharide, 
but not the disaccharide.  This was discovered by hydrazinolysis and led to the discovery of a B. 
anthracis specific sugar identified as anthrose  (23).  The BxpB protein plays a role in 
incorporation of the BclA glycoprotein into the exosporium (25).     
 
 Also reported to be in the exosporium and likely the nap is the protein InhA (immune 
inhibitor A).  It is reported to be the major antigen on the outside of B. cereus spores.  The BclA 
protein is coated with sugars, a major portion comes from the rmlACBD operon adjacent to the 
bclA operon on the chromosome (92).  The rmlACBD operon encodes enzymes necessary for 
rhamnose biosynthesis.  Although spores from a rmlD mutant were more efficiently taken up by 
macrophages and bound more efficiently to macrophages, they were not more virulent in a 
guinea pig model (92).  Interestingly, macrophages can recognize and internalize collagen via the 
mannose receptor, and this may recognize the collagen-like proteins of the nap (145).    
 
The Cap and ExsY 
 
 ExsY is required for complete formation of the exosporium of B. anthracis (85).  
Assembly of the exosporium in an exsY mutant is halted after partial formation of a polar 
exosporium-like structure termed the “cap” (85).  The exosporium cap produced could readily be 
stripped off under growth in liquid media (85).  The exsY mutant grown on solid media retained 
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the cap structure.  An exsY mutant also appears to lack BxpB, showing a relationship between the 
two proteins. The mutant spores ruptured a novel sac-like structure in the exosporium during 
germination and outgrowth (85, 86).  This sac was still evident when ∆exsY spores were grown 
in solid media.  ExsY is found not only incorporated into high molecular weight complexes with 
the BclA protein, but also found in monomers, dimers, and trimers (85, 86).  BclA is not 
assembled into the exosporium but rather is secreted into the supernatant in an exsY cotY double 
mutant, further suggesting an interaction between the two proteins.  ExsY has a consensus σK 
promoter, consistent with its expression during the spore coat/exosporium assembly phase of 
sporulation.  
 
 The presence of the cap has led to the development of the bottle cap model for spore 
germination (97).  According to this model, ExsY plays a role in the development of the 
exosporium beyond the cap.  This cap may be the first structure of the exosporium to be 
assembled, since it appears first under TEM analysis.  Alanine racemase, an enzyme commonly 
found in the exosporium, was shown to only be localized in the three quarters of the exosporium 
that is not part of the cap (97).  This suggests that the assembly of the cap and the assembly of 
the rest of the exosporium are sequential and separate, and their formation discontinuous.  
During germination and outgrowth, the emerging cell bursts through the exosporium and 
underlying layers, and this always appears to be at the end of the spore that corresponds to the 
cap (97).  This led to the prediction that the cap is designed to facilitate the emergence of the 
outgrowing cell.   
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BclA 
 
 BclA (Bacillus collagen-like protein of anthracis) has been found in all the B. cereus 
family members. The BclA protein is comprised of distinct N-terminal and C-terminal domains, 
with a series of collagen-like GPT repeats comprising the extensive middle portion of the 
protein.  Several aspects of the BclA protein are similar to collagen, and lead to the prediction 
that BclA can form a triple helical structure. A glycine residue occupies every first amino acid in 
the repeating GXX triplet sequence. 39% of the non-glycine residues in the repeat are prolines, 
which are essential for triple helix stabilization by limiting rotation of the polypeptide chains (69, 
94, 194).  Computer modeling predicts that BclA exists in a coiled conformation (19).  rBclA 
naturally forms a triple helical structure upon heating and cooling the protein (75).  The native 
BclA protein confers exceptional stability, and may act as a protective shield to the spore.     
 
 The BclA N-terminus domain is similar in structure to members of the TNF family, and 
its role is currently unknown.  N-terminal sequencing of the protein extracted from spores has 
shown that the first 19 residues of the protein are processed to remove 19 aa from the N-terminus 
(15, 19).  The N-terminus also faces towards the basal layer in the orientation of the exosporium 
(19). 
 
The internal repeat region is hydrophobic with 70 collagen-like triplet repeats (GXX) and 
54 GPT triplets (19). The hydrophobic nature of BclA may explain the general hydrophobicity of 
the entire spore (78).  Between residues 41-232 is the repeat of ((GPT)5GDTGTT)2 known as the 
BclA repeat (15).  Variations in the BclA repeat, as well as parts of the N and C termini 
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displaying sequence polymorphisms, allow species and strain discrimination (99, 83).  
Differences in the number of repeats also correspond to the length of the hair-like nap on the 
exosporium (83).  Mutants of bclA are apparently devoid of a visible nap on the outer surface of 
the exosporium (19).   
 
The 134 aa C-terminal domain (CTD) is essential for forming the triple helical structure 
of the BclA protein.  The CTD  itself can naturally form a heat stable triple helix (75).  This 
domain also faces away from the spore in the exosporium, and is the most external part of BclA. 
Recombinant BclA is resistant to many proteases, but is highly susceptible to collagenases, 
whereas the native glycosylated BclA is resistant to both (75, 72).  Collagenase treatment of the 
rBclA leads to digestion of the amino terminal of the collagen like region, but the CTD remains 
resistant (72).  BclA also has a dissociation constant equivalent to a triple helix when examined 
by circular dichroism (75).  This CTD most likely acts as the stabilizing point, to which the rest 
of the BclA protein is folded.  rBclA will spontaneously refold into a triple helix, starting with 
the CTD (75).  BclA is predicted to have a lollipop structure, with the collagen-like region 
containing the stalk and the CTD forming a triple helical head of the globular protein (69).  The 
globular CTD domain is strikingly similar to the C1q protein of compliment and tumor necrosis 
factor.  Both BclA and C1q have been shown to be capable of interacting with the SP-C 
component, a major part of the lung alveolar surfactant layer (69). 
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 The structure and role of BclA in the pathogenesis of B. anthracis is just now being 
elucidated.  BclA electrophoretically migrates at >70 kDa, which is much greater than the 34 
kDa expected from its amino acid sequence. This is potentially due to the large content of 
prolines, which have been shown to modify the migration of collagen-like proteins (15, 194).  
These collagen-like proteins are extremely rare in prokaryotes (19, 94).  The repeated threonine 
residues throughout the repeat may serve as multiple sites of O-linked glycosylation (83).  These 
proteins can form triple helical structures, without the need for hydroxyprolines that eukaryotes 
use in their collagen triple helices.  Threonines can substitute by making direct hydrogen bonds 
to neighboring carbonyls to stabilize the structure (195).  This stabilization can be enhanced by 
glycosylation of the threonines. Glycosylation of threonine residues in worm collagen greatly 
stabilize the triple helices (195).  The glycosylation of BclA may lead to resistance to protease 
activity. The ability of bacterial collagen-like proteins to form triple helices in vitro has been 
recently shown with the streptococcal collagen-like proteins (95, 96).  They too contain a long 
collagen-like internal region and may be involved in adhesion.      
 
 Two O-linked oligosaccharides, a 715 kDa tetrasaccharide and a 324 kDa disaccharide 
are released from spore- and exosporium-associated BclA after hydrazinolysis treatment (19, 
23).  Each oligosaccharide is probably attached to BclA by a GalNAc linker.  The tetrasaccharide 
is found in multiple copies in the collagen-like region of BclA, and the disaccharide is most 
likely attached outside this region (74).  The disaccharide is composed of a rhamnose residue and 
a component identified as 3-O-methyl-rhamnose. The tetrasaccharide is 2-O-methyl-4-(3-
hydroxy-3-methyl-butamido)-4,6-dideoxy-β-D-glucopyranosyl-(1Æ3)-α-L-rhamnopyransol-
(1Æ3)-α-L-rhamnopyranosyl-(1Æ2)-L-rhamnopyranose.  The terminal end sugar is 2-O-methyl-
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4-(3-hydroxy-3-methylbutamido)-4,6-dideoxy-D-glucose. This terminal sugar has been named 
anthrose.  The anthrose sugar moiety is not found in the other members of the B. cereus family, 
although they all contain the BclA protein.  This sugar could be exploited as a novel target of 
diagnostic kits (74).  These sugars have been synthesized in vitro (70, 71). 
 
 Synthetically synthesized GPT repeats also are stabilized by glycosylation (69).  
Recombinant BclA expressed in E. coli hosts is not glycosylated.  BclA is rarely found without 
being glycosylated, hinting at a linked production/glycosylation pathway (19).  When the native 
protein in the spore is extracted and treated with trifluoromethanesulfonic acid (TFMS) to 
remove the glycosylation, the protein still retains a small portion of the sugar moieties (15, 19). 
A bclA mutant sporulates and germinates with kinetics similar to wild-type strains (19). The bclA 
gene has a putative σK promoter upstream of the open reading frame, consistent with sporulation 
stage expression of proteins produced in the mother cell.  This open reading frame is followed by 
two inverted repeats after the termination codon.     
     
 The highly glycosylated nature of BclA may play a role in binding of the spores by 
carbohydrate recognition molecules of antigen-presenting cells (APCs; 19).  This glycosylation 
also may protect the protein coat and spore from enzymatic cleavage and help exclude some 
molecules from gaining access to the spore. It may also play a role in adherence, as several other 
collagen-like proteins in prokaryotes have been predicted to be adhesins (95, 96, 152).  bclA 
mutant spores presented no significant change in virulence in a mouse model of infection (77) 
but the course of disease was modified (personal communication).  BclA is a major 
immunodominant antigen of the spore. This response is not to the extensive glycosylation of the 
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spore, which can elicit an immune response, but is to the protein component (15).  Using a live 
or irradiated spore vaccine, an immune response to the tetrasaccharide itself can be made, and is 
another potential target for future vaccines (82, 76).  BxpB, ExsFA, and ExsFB play a role in 
BclA being incorporated into the nap layer of the exosporium (80). 
 
BclB 
  
 Recently, a second collagen-like spore glycoprotein of B. anthracis was identified (89).  
This new glycoprotein was named BclB for Bacillus collagen-like protein B.  Other exosporium 
glycoproteins, ExsJ and ExsH, have been identified in B. cereus and B. thuringiensis, but have 
not been found in B. anthracis.  Both ExsJ and ExsH have been found to migrate during 
electrophoresis as a >205 kDa species. ExsJ has been found to contain rhamnose, galactosamine, 
and a third unidentified sugar.  ExsH has a region of collagen-like repeats, like ExsJ, but the 
carbohydrate composition has not been identified (89).  The bclB determinant was predicted to 
have been formed from a unique crossover event between ExsH-like or ExsJ-like genes derived 
from B. cereus or B. thuringiensis (89). 
  
Upon urea extraction of spores of B. anthracis, two high molecular weight glycoproteins 
were identified (89). One was the well characterized BclA protein, and the second, migrating at 
205 kDa, was the newly identified BclB protein. When deglycosylated, BclB migrated as a band 
of about 83 kDa, suggesting that it has a collagen-like triple helix structure similar to BclA or is 
an extensively glycosylated protein. Using GC-MS analysis, 3-O-methyl rhamnose, rhamnose, 
and galactosamine were found to be part of the BclB glycoprotein, all three of which are also 
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present in BclA (89).  BclB contains a repeated GXX motif, GITGVTGAT, which has been 
named the BclB repeat. The role of BclB in the B. anthracis spore was unknown and the subject 
of this research project. 
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 Materials and Methods 
 
Bacterial Strains 
  
 The bacterial strains used in this study are listed in Table 2.  All E. coli strains were 
cultivated in L Broth or Tryptic Soy Broth (TSB, Oxoid).  All Bacillus anthracis strains were 
grown in Brain Heart Infusion broth (BHI, Difco), with or without 0.5% glycerol, or L Broth, 
unless otherwise noted.  Agar plates were made by mixing the above broths with 1.5% agar prior 
to autoclaving.  Antibiotic selection was used for the maintenance and selection of plasmids and 
recombination events, and was used at the concentrations noted in Table 3.      
    
Table 4 contains a table of the plasmids used in this study.  Frozen stocks of all clones 
and constructs was made by heavily inoculation of freshly grown cultures into BHI broth 
containing 20% glycerol and placed on dry ice.  After quick freezing on dry ice, the cryo-tubes 
were placed at -80oC for long term storage and recorded in the Stewart Laboratory stockbook.   
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 Strain Genotype Marker
E. coli
DH5α F- φ80lacZ∆M15 ∆(lacZYA-argF)U169 deoR recA1 endA1 hsdR17(rk-, mk+) 
phoA supE44 thi-1 gyrA96 relA1 λ-
GM48 F- λ- dam-3 dcm-6 thr-1 leuB6 ara-14 tonA31 lacY1 tsx-78 glnV44(Am) 
 galK2(Oc) galT22 thi-1 
M15 see Qiagen manufacturer's specifications
Able K lac(LacZω-) [Kanr McrA- McrCB- McrF- Mrr- HsdR(rK-)] KanR
[F′ proAB lacIqZ∆M15 Tn10 (Tetr)]
B. anthracis
∆Sterne 7702 pX01- pX02-
MUS1692 ∆Sterne ∆bclB  Kan::bclB KanR
CTL292 ∆Sterne ∆bclA  63-907 KanR
Table 2: Bacterial Strains used in this study. 
 
 
 
 
 
Chloramphenicol Kanamycin Erythromycin Neomycin Ampicillin Gentamicin
E. coli 10 µg/ml 25 µg/ml 250 µg/ml N/A 100 µg/ml N/A
B. anthracis 10 µg/ml 50 µg/ml 5 µg/ml 25 µg/ml N/A 2.5 µg/ml
Table 3: Antibiotic Concentrations  
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 Plasmids Description Markers
pREP4 Qiagen LacI inducible repression plasmid KanR
pQE30 Qiagen protein expression vector AmpR, CmR
pBT3571 BclA protein expression vector, pQE30 BclA ORF AmpR, CmR
pBT3642 BclB protein expression vector, pQE30 BclB ORF AmpR, CmR
pUTE583 Koehler B. anthracis  cloning vector CmR, EryR
pGS3632 Recombination vector with BclB flanking regions and KanR marker AmpR, KanR, EryR
Table 4: Plasmids used in this study 
 
 
DNA Manipulations 
 
 Plasmid DNA from E. coli was isolated by following the Wizard Plus SV Plasmid DNA 
purification system (Promega) protocol or by the procedure of Birnboim and Doly (149).   
Quantification of the purified plasmid DNA was spectrophotometrically determined using the 
Nano-Drop ND-1000 spectrophotometer.  Restriction endonuclease digestions were performed 
under the conditions set forth by the manufacturers.  A characteristic digestion would be 10 µl of 
plasmid DNA at a concentration of 150 ng/µl; combined with 17 µl ddH20, 3 µl of the 
corresponding restriction digestion buffer, and 1 µl of the restriction enzyme.    
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Clean up of plasmid and chromosomal DNA, ligation reactions, and PCR products was 
accomplished by extraction with an equal volume of TE-saturated phenol (pH 8.0) followed by 
extraction with an equal volume of chloroform.  One final centrifugation (time and rpm or g 
value) was performed to fully remove any residual phenol/chloroform from the samples.  A 0.1 
volume of 3M Na acetate (pH 5.0) was added to the DNA, followed by 2.5 volumes of 95% 
chilled ethanol.  The mixture was incubated on ice for 10 minutes, followed by a final spin of 10 
minutes in a Marathon 16Km microcentrifuge (Fisher Scientific).  The ethanol supernatant was 
decanted, and the remaining DNA pellet was placed in a Centrivap Concentrator (Labconco) for 
20 minutes to remove any residual ethanol from the samples.  The dried DNA pellet was 
resuspended in 20 µl of ddH20.  If the product was to be ligated post-precipitation, the two 
digested products would be mixed at the appropriate ratio prior to precipitation with ethanol.     
Screening of isolated plasmid DNA or digested restriction products was accomplished by 
electrophoresis in a 1% agarose gel containing ethidium bromide (EtBr, 0.5 µg/ml) in tris-acetate 
electrophoresis buffer.  The DNA was premixed with 3 µl DNA loading buffer (Promega) and 
loaded into individual wells of the gel.    
Gel purification of DNA was accomplished using the procedure provided by the 
Quantum Prep Freeze N’ Squeeze DNA gel purification kit (BioRad) or the Qiaquick Gel 
Extraction Kit (Qiagen).  DNA ligations were performed at 16˚C using T4 DNA ligase in a 20 µl 
volume.  When the DNA recovery rates were especially low due to low-copy plasmids or loss of 
samples, DNA pellets after ethanol precipitation were resuspended in 9 µl of dH2O and added to 
1µl 10x T4 DNA ligase buffer and 0.5 µl T4 DNA ligase. Ligations were usually performed with 
a ratio of insert to vector of 3:1.  Ligation was allowed to continue overnight (14-20 hours) at 
16oC in a Microcooler II constant temperature chamber (Boekel Scientific). 
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Transformation of E. coli 
 
 Frozen competent cells were thawed on ice.  5-10 µl of ligated DNA or 1-2 µl of pure 
plasmid DNA was added to 50 µl of cells and allowed to sit on ice for 10 minutes.  The cell-
DNA mixture was heat-shocked by incubation of the mixture in a 37oC water bath for 5 minutes.  
Immediately after heat shocking, 250 µl of L broth was added to the mixture, and the cells were 
incubated for 60 min. at 37oC with shaking at 250 rpm.  After a hour of incubation the broth was 
plated in 100 µl aliquots on plates containing the appropriate antibiotic, or resuspended in 5 ml 
of L broth with antibiotics and incubated overnight at 37oC.    
 
PCR 
 
 All primers were obtained from IDT technologies (Coralville, IA).  Primers were 
resuspended in 1 ml ddH20.  Aliquots of primers diluted to 25 ng/µl were prepared and stored 
frozen at  -20oC.   PCR reactions were performed using Ex-Taq polymerase as outlined by the 
manufacturer (Takara).  A typical reaction would be: 10 µl 10X reaction buffer, 8 µl dNTPs, 3 µl 
primer 1 (25 ng/µl), 3 µl primer 2 (25 ng/µl), template DNA (2 µl of chromosomal miniprep 
DNA, 0.2 µl if plasmid DNA), 0.5 µl Ex-Taq enzyme, 73.5 µl ddH20 for a total of 100 µl per 
reaction.   Reactions were allowed to continue for 35 cycles, at TMs appropriate for the primers 
used.  Extension times were set conservatively, corresponding to approximately 1 minute per kb 
of expected PCR product size. 
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 Primers Sequence
BclB KO Construction
bclB 5pK ggtaccgcagaaggaaaattaagttcg
bclB 3pS gtcgacactaattcatctcgctttaac
bclB soeFB aacaaaggatccctcattccacatttttgtttcctaattaac
bclBsoeRB caaaaatgtggaatgagggatcctttgttacaatgttaatagg
BclA KO Screening
5pbclAXh aactcgagctgaaggcaatgtatc
3pbclAXh aactcgagcaattctctcctctag
qbclA5pB cgggatccatgtcaaataataattatt
qbclA3pS agcgtcgacttaagcaactttttcaat
Backbone Screening
pute5p cgataccgtcgacctcg
pute3p aacaaaagctgggtacc
Intact BclA screening
bclA5pXm aacccgggctgaaggcaatgtatc
bclA3pS agcgtcgaccaattctctcctctag
Intact BclB screening
bclB5pK ggtaccgcagaaggaaaattaagttcg
bclB3pS gtcgacactaattcatctcgctttaac
BclA protein
qbclA5pB cgggatccatgtcaaataataattatt
qbclA3pS agcgtcgacttaagcaactttttcaat
BclB protein
qbclB5pB cgggatccatgaaacagaatgacaaattatg
qbclB3pS agcgtcgacttagacgatattaagacctgc
 
Table 5: Primers used in this study 
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PCR products were cloned into either the Invitrogen pCR Topo 2.1 TA or the Stratagene 
pSCα-1 cloning vectors in accordance with the supplier’s protocol.  DNA inserts were 
sequenced using the M13 upstream and downstream primers on an Applied Biosystems 3730 
DNA Analyzer using Applied Biosystems Prism BigDye Terminator cycle sequencing 
chemistry, and the sequences compared to the TIGR sequenced genome of the Bacillus anthracis 
Sterne strain.  
 
Electroporation conditions 
 
 An overnight culture of Bacillus anthracis was grown in BHI broth with 0.5% glycerol 
with appropriate antibiotics.  0.5 ml of this overnight culture was used to inoculate 100 ml of 
BHI + 0.5% glycerol in a 500 ml Erlenmeyer flask.  The flask was allowed to incubate at 37oC 
with shaking until the OD600 reached 0.6.  The culture was then passed thru a disposable 
Analytical Test Filter Funnel apparatus with a pore size of 0.45 µm (Nalgene).  The cells were 
then washed with 25 ml of ice cold Electroporation buffer, and this step was repeated three 
times.   After the third wash, the filtered cells were recovered in 5 ml of ice cold Electroporation 
buffer and placed on ice.   
 1 mm electroporation cuvettes were loaded with 100 µl of cells and 1 µg of high quality 
plasmid DNA obtained from a dam- host. After loading, the cuvettes were pulsed at 25 µFD, 100 
Ohms, at 2.5 kV.   Immediately after pulsing, the cell/DNA mixture was resuspended in 1 ml of 
BGGM.  After incubation at 37oC for 1 hour, aliquots were plated onto BHIA plates with the 
appropriate antibiotics and allowed to incubate overnight at 37oC. 
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Isolation of Chromosomal DNA. 
 
 B. anthracis strains were cultured in 10 ml TSB with appropriate antibiotic selection at 
37ºC. The cells were harvested by centrifugation, washed with 10 ml TE buffer (0.01 mM Tris-
HCl, 0.001 mM EDTA, pH 8.0), and the cell pellets frozen at -25ºC for several hours to 
overnight and then thawed, resuspended with 0.1 ml TE, and incubated at 37ºC for 30 minutes to 
induce autolysis. The cell lysate was treated with RNaseA (25 µg) and N-lauryl sarcosine 
(0.8%).  Proteinase K (25 µg) was then added and the sample incubated at 60ºC for 1 hr. The 
sample was then cooled on ice and sequentially extracted with TE-saturated phenol and 
chloroform. The DNA was either dialyzed against distilled water at 4ºC overnight or precipitated 
with ethanol as described above and then resuspended in sterile distilled water. 
 
Preparation of Competent E. coli. 
 
 Cells from an E. coli competent cell stock was streaked onto a prewarmed L agar plate 
and incubated overnight at 37oC.  One colony was picked and inoculated into 5 ml L broth in a 
15 ml polypropylene conical centrifuge tube (Fisher Scientific) and incubated overnight with 
shaking at 37oC.  1L of prewarmed L broth (with appropriate antibiotics) was inoculated with 1 
ml of the overnight culture and incubated at 37˚C with shaking.   Growth was allowed to 
continue until absorbance at 600 nm reached 0.2 for recA+ strains or 0.6 for recA-negative 
strains.  The culture was then chilled on ice for 10 minutes.  The culture was dispensed into 6-
250 ml centrifuge bottles, and centrifuged at 3,000 g for 10 minutes.   After discarding the 
supernatant the pellets were resuspended in 50 ml of 0.1 M CaCl2 (4oC).  The bottles were placed 
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in an ice bath for 10 minutes, followed by another spin at 3,000 g for 10 minutes.  The 
supernatant was again decanted and the pellets were resuspended in 10 ml of 0.1 M CaCl2 and 
pooled.   The pooled competent cells were kept on ice for 20 hours.  After 20 hours, 2.5 ml of 
sterile glycerol were added, and the competent cells were aliquoted into sterile microcentrifuge 
tubes, quick-frozen on dry ice, and then stored at -80oC for future use.    
 
Protein Production 
 
 The ORFs of selected genes were PCR amplified and cloned into the plasmid pQE30 
(Qiagen), to allow for inducible expression in E. coli by the addition of IPTG.  These plasmid 
constructs were transformed into either GM48 or Able K strains of E. coli bearing the pREP4 
plasmid that encodes the lacI repressor, to minimize basal transcription of the cloned ORF.  A 5 
ml overnight culture of the plasmid-containing bacteria was inoculated into 1 liter of prewarmed 
LB broth containing antibiotics and incubated with shaking for several hours at 37oC.  When the 
O.D.600 reached 0.6, 2 ml of 0.5 M IPTG was added to the flask to induce expression of the His-
tagged protein.  After 1 hour of induction, the culture was centrifuged for 10 minutes at 5,000 
rpm using centrifuge bottles in a GSA rotor in a Sorvall RC5B Plus centrifuge.  Cell pellets were 
frozen at -80oC until the protein purification procedure was carried out . 
 Purification of proteins was done using a His-Spin Protein Miniprep purification kit 
(Zymo Research). Each cell pellet was resuspended with 1 ml of Zymo His-Binding Buffer, for a 
total of roughly 2-3 ml per culture.  1g of .1 mm glass beads (Biospec) was added into bead-
beating tubes along with 1 ml of the resuspended cell pellet.  The bead-beating tubes were bead-
beat for 4-1 minute pulses, and centrifuged for 5 minutes in a microcentrifuge at 10,000 g to 
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remove the beads and cell debris.  The supernatant was removed and the His-tagged proteins 
purified over the his-purification columns as per the manufacturer’s suggested protocol.  The 
eluted fractions were pooled and then dialyzed twice against PBS or distilled water at 4oC 
overnight. Protein concentrations were determined using a Nano-Drop ND-1000 
spectrophotometer and protein stored at -80oC until use.   Purity of the protein was assessed by 
SDS PAGE  
 
Production of Rabbit Polyclonal Antibodies 
 
 A vial of Ribi adjuvant plus MPL + TDM + CWS Emulsion (Corixa) was warmed up to 
42oC for 10 minutes.  1 ml of sterile saline was added to the emulsion with a 21 gauge needle 
and vortexed vigorously for 3-4 minutes.   250 µg of purified protein was mixed with saline to a 
volume of 500 µl.  This mixture was added to 500 µl of the adjuvant emulsion for a final volume 
of 1 ml.  This immunogen sample was mixed vigorously by vortexing.  Six subcutaneous 
injections were given and the rabbit was boosted after 3, 6 and 9 weeks.  Prior to each boost, a 
bleed of 10 ml was performed.  The resulting serum was tested for reactivity to recombinant 
protein by Western Blot analysis.  When the desired antibody titer was reached, the rabbit was 
sacrificed and a terminal bleed was obtained.   
 The collected blood was allowed to clot at 4oC for 1 hour.  A swab was used to remove 
adherent material from the top of the tube.  Tubes were centrifuged for 10 minutes at 5,000 rpm 
in a SM-24 rotor (Sorval).  Clear sera were removed and aliquoted into labeled cryo-freeze tubes 
(Corning).  These were then frozen and stored at -80oC until use.  
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Sporulation Assays 
 
An overnight TSB culture of B. anthracis was used to inoculate fresh media to an initial 
OD600 of  0.2.  For sporulation in broth, 1 ml of culture was added to 9 ml broth and put in a 30oC 
or a 37oC shaker overnight.  For sporulation on agar plates, 2 swabs of culture were distributed 
evenly across the surface of a 100 x 15 mm plate and then incubated at 30oC or 37oC. At various 
time points, cells were collected and split into two even aliquots.  One aliquot of spores went in a 
65oC water bath for 30 minutes to obtain a spore count (resistance to heat killing).  The other half 
was diluted directly and plated for total viable CFUs. 
 
Production of Spores 
 
 To obtain large quantities of spores, a 5 ml exponential phase culture was grown under 
antibiotic selection.  Swabs of the culture were then inoculated evenly and heavily onto nutrient 
agar plates and incubated at 30oC for 5 days.  Samples were taken and examined under phase 
contrast microscopy to assay the ratio of spores:vegetative cells.  When greater than 95% of the 
samples were released spores, sterile swabs dipped in PBS were used to gently harvest the spores 
off the surface of the nutrient agar plates.  The collected spores were pelleted in a 
microcentrifuge, and the supernatant discarded.  The spore pellet was washed 3x in PBS to 
remove residual cell debris.  Storage of the spores was done at room temperature or at 4oC. 
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Resistance Properties of B. anthracis Spores 
 
Heat resistance. Spores from the wild-type and mutant strains were resuspended in PBS at a 
concentration of 108 cfu/ml in tightly capped tubes (to prevent evaporation volume loss) and 
placed in a 65°C water bath. Samples were removed at hourly intervals, dilutions prepared in 
sterile PBS, and plated on BHIA plates which were then incubated overnight at 37˚C for viable 
count determinations. 
 
Resistance to ultraviolet irradiation. Spores were resuspended in PBS at a concentration of 
106 spores/ml, placed in a sterile glass petri dish, and irradiated with a UV germicidal lamp (dose 
of 700 erg/mm2). Samples were removed at 30 sec intervals diluted in sterile PBS, and plated on 
BHIA plates for viable count determinations.  
 
Resistance to organic solvents (chloroform and ethanol). 50 µl of chloroform was added to 
0.45 ml of spores in a 1.5 ml polypropylene microcentrifuge tube, vortexed vigorously, and 
incubated at room temperature for 10 min. An aliquot was then removed, serially diluted in PBS, 
and plated on BHIA plates for viable count determinations. For resistance to ethanol, 50 µl of the 
spores were added to 0.45 ml of 70% ethanol in a 1.5 ml polypropylene tube, vortexed, 
incubated, diluted, and plated. 
 
Resistance to disinfectants. Spores were tested for resistance to phenol, bleach (sodium 
hypochlorite), and a quaternary ammonium salt disinfectant (Roccal-D [Upjohn]). To determine 
the level of resistance to these disinfectants, 50 µl of the spores were added to 0.45 ml of 5% 
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(w/v) phenol, bleach (1:32 dilution of bleach [5.25% sodium hypochlorite]), or 1:200 dilution of 
Roccal-D (stock was 20% alkyl dimethyl benzyl ammonium chloride) in 1.5 ml polypropylene 
microcentrifuge tubes. The samples were vortexed vigorously and kept at room temperature. 
After 10 minutes, aliquots were removed from each, serially diluted in PBS, and plated on BHIA 
plates for viable count determinations.  
 
Germination Assay 
 
 To assay germination, 1x104 spores in 100 µl were added to 900 µl of DMEM + low 
glucose, or 900 µl DMEM + low glucose (NOTE: define low glucose) and 10% FBS.   After 1 
hour, the sample was divided and half placed at 65oC for 30 minutes and plated on BHIA to 
obtain a plate count of ungerminated spores, and the other half was directly plated on BHIA to 
obtain a total CFU count.  The difference between the two counts was equivalent to the number 
of spores germinated. 
 
Macrophage Infection Assay
 
105-106 RAW 264.7 Mφ were dispensed into 24-well tissue culture plates (Falcon) and 
were incubated overnight in Dulbecco's Modified Eagle Media (DMEM) with low glucose plus 
10% heat inactivated [65ºC for 1 hr] fetal bovine serum (FBS). Endospores were diluted in 
DMEM with 10% FBS and then immediately added to wells at an MOI of 1:1 or 10:1 
spores:macrophages. To maximize the number of endospores interacting with Mφ, the plate was 
centrifuged at 1,000 rpm for 5 min in a Sorvall 6000D tabletop centrifuge (Sorvall Instruments) 
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equipped with a Sorvall H100B rotor that was prewarmed to 37°C. After centrifugation, the 
plates were incubated for an additional 30 min at 37°C in an H2O saturated atmosphere with 5% 
CO2 to allow for germination and outgrowth of endospores. The culture medium was aspirated 
from each well, the Mφ were washed and the medium was replaced with fresh medium 
supplemented with 50 µg/ml gentamicin and incubated for 30 min at 37ºC to eliminate any 
unphagocytosed germinated endospores and extracellular vegetative cells. The medium was 
removed and the cells washed twice with fresh antibiotic-free DMEM and resuspended in fresh 
prewarmed medium. Intracellular bacterial numbers were then quantified by dilution plating after 
Mφ from triplicate wells were lysed with distilled water (lysis was observed under light 
microscopy). The bacteria were serially diluted in PBS and plated on BHIA plates directly (total 
viable counts) or after heating for 30 minutes at 65ºC (ungerminated spore counts).  
 
SDS PAGE   
 
10 mg (wet wt) of spores were either extracted by boiling the spores in a urea buffer (50 mM 
Tris-HCl, pH 10, 8 M urea, 2% 2-mercaptoethanol) or by boiling the spores in SDS sample 
buffer (50 mM Tris-HCl, pH 6.8, 4% SDS, 10% glycerol, 2% B-mercaptoethanol, 0.02% 
bromophenol blue) for 10 minutes.  The extracted spores were pelleted at 10,000 g for 10 
minutes at room temperature.  The supernatant was removed and used to load individual lanes of 
a 4-20% gradient Tris-HCl protein gel (Bio-Rad) and electrophoresed in Tris-glycine-SDS 
buffer.  Gels were stained with coomassie brilliant blue.   
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Analysis of Glycoproteins and Phosphoproteins 
 
 Proteins separated on 4-20% Tris-HCl gradient SDS PAGE gels were stained with 
glycoprotein stain (Pierce) or Pro-Q Phosphoprotein stain (Invitrogen) as per the suggestions of 
the supplier. Images of the phosphoprotein stained gels were taken at 340 nm.     
 
Western Blots  
 
After proteins were resolved by SDS PAGE, the gel was washed twice with cold transfer 
buffer.  The gel was transferred onto a nitrocellulose (NC) membrane using a BioRad transfer 
cassette apparatus.  The NC membrane was removed and placed in blocking buffer with 
StartingBlock (Pierce) for 1 hr with gentle shaking.  The blocking reagent was discarded, and1-3 
µl of primary rabbit polyclonal antiserum was added in wash buffer to the blot and placed on a 
gyrotary shaker for 1 hour at room temperature.  After two quick washes in wash buffer, the blot 
was washed 6X for 5 minute intervals with wash buffer. 
 The wash buffer was discarded, and 1 µl of goat anti-rabbit IgG-alkaline phosphotase 
conjugate (Vector) was added in wash buffer and allowed to shake for 1 hour. After two quick 
washes in wash buffer the blot was washed 8x in 5 minute intervals with wash buffer.  
Development of the blot was performed using the AP Conjugate Substrate kit (BioRad) to the 
manufacturer’s instructions and allowed to develop for 10 minutes. The blot was blotted dry with 
a paper towel.  
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Protein Identification Via MALDI-TOF MS Analysis 
 
 Coomassie stained gel bands were excised from the gel using a razor blade, transferred to 
a microcentrifuge tube, and minced to approximately 1-2 mm3 pieces.  The gel pieces were first 
equilibrated for 15 minutes in 500 µl 100 mM ammonium bicarbonate solution at RT with gentle 
mixing.  Bands were then destained with 3-15 minute washes in 500 µl of 50/50 
acetonitrile/100mM ammonium bicarbonate wash.  Gel pieces were then dehydrated for 20 
minutes in a fresh aliquot of acetonitrile.  The acetonitrile was replaced with 150 µl 10 mM DTT 
in 100 mM ammonium bicarbonate.  Gel bands were then rehydrated and reduced at 56oC for 30 
minutes.  The reducing agent was removed and the protein bands were alkylated in-gel with 100 
µl 50 mM iodoacetamide in 100 mM ammonium bicarbonate for 30 minutes in the dark.  The gel 
pieces were then rinsed with wash solution before a final round of dehydration in acetonitrile.   
 Protein bands were rehydrated for 2 hours at 4oC in a 20 µg/ml solution of modified 
TPCK-treated porcine trypsin (Promega)  At the end of the rehydration period the trypsin 
solution was replaced with 40 mM ammonium bicarbonate/10% acetonitrile and the proteins 
digested overnight at 37oC  The digested protein solution was recovered from the protein gel 
pieces and transferred into 600/300/100 acetonitrile/water/10% TFA acid.  The gel pieces were 
then extracted twice for 10 minutes in the same solution.  The pools were frozen with liquid 
nitrogen and lyophilized. Dried digests were reconstituted in 990/10 water/88% formic acid for 
desalting with a micro C18 Ziptip (Millipore).  Each sample was cycled in and out of a Ziptip 15 
times for peptide loading onto the column.  The Ziptip loaded with protein were washed 5 times 
with the water/formic acid solution, followed by elution with a 700/290/10 
acetonitrile/water/88% formic acid solution. 
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 0.6 µl of the elution was mixed with 0.6 µl of alpha-cyano-4-hydroxycinnamic acid 
(CHCA) matrix solution.  A 0.4 µl aliquot of the mixture was deposited on a polished stainless 
steel target and allowed to crystallize.  Mass Spectra were acquired using an Applied Biosystems 
Inc. 4700 MALDI TOF/TOF MS with a 355 nm Nd:YAG laser (200 Hz) in the positive ion 
delayed extraction reflector MS or positive ion MS/MS mode.  The eight most intense ions were 
selected for analysis for MS/MS.  Database searches were performed in the automated batch 
mode with Applied Biosystems’ GPS Explorer (version 3.6).  Data were submitted to Matrix 
Science’s Mascot search engine for queries against the NCBI nr bacteria protein database. 
 
Transmission Electron Microscopy
 
To the buffer-washed spores, 1 ml of a 2% glutaraldehyde, 0.1 M sodium cacodylate solution 
containing 0.1% ruthenium red (Electron Microscopy Sciences, Fort Washington, PA) was added 
and incubated for 1 hour at 37°C. Each pellet was then washed in cacodylate buffer and fixed for 
3 h at room temperature in a 1% osmium tetroxide (Electron Microscopy Sciences), 0.1 M 
sodium cacodylate solution containing 0.1% ruthenium red. A negative control was treated 
identically, but ruthenium red was omitted from these two steps. Spores were washed in buffer 
and embedded in 3% agar (EM Science, Gibbstown, NJ). Dehydration involved sequential 
treatment with 25, 50, 75, 95, and 100% acetone. Polymerization was carried out at 60°C in 
Epon/araldite resin.  Electron microscopy sections were cut at 85 nm thickness and put on 200 
mesh carbon-coated copper grids and then stained with a 2% uranyl acetate solution (Electron 
Microscopy Sciences) for 40 min at 37°C. The sections were then treated with Sato's Triple Lead 
for 3 minutes, washed in ultrapure water, and stained again for 18 minutes in 5% uranyl acetate, 
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followed by one final wash and were observed by transmission electron microscopy with a JEOL 
1200EX electron microscope.  
 Immunogold labeling of embedded spores was performed after fixation of spores in a 2% 
gluteraldehyde and 2% formaldehyde PBS solution.  After dehydration and embedding as listed 
above, the cut grid sections were blocked in a 1% BSA solution for 30 minutes.  The grids were 
thrice washed in PBS, and the primary antiserum was added to the grids at a concentration of 
1:25 in Incubation buffer (Aurion).  Following a one hour incubation at room temperature, the 
grids were washed 6X in Incubation buffer, and were incubated with 1:25 goat anti-rabbit 
secondary conjugate with 15 nm colloidal gold (Aurion) and incubated for two hours.  After a 
series of washes in PBS, the grids were post-fixed in 2% gluteraldehyde on 0.1 M PBS for 5 
minutes followed by washes in PBS and distilled water.   
 
Scanning Electron Microscopy
 
B. anthracis spores were fixed overnight at 4°C in 20 volumes of modified Karnowsky's 
fixative (2% paraformaldehyde, 2.5% glutaraldehyde, 1.7 mM CaCl2 in 0.1 M cacodylate buffer 
[pH 7.4]). After the spores were fixed, they were washed twice in 0.1 M cacodylate buffer (pH 
7.4) and post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer overnight at 4°C. After 
the cells were washed twice in double-distilled water, they were resuspended in double-distilled 
water, mounted on coverslips coated with poly-L-lysine, and dehydrated in a series of alcohol 
solutions (25, 50, 70, 95, and 100%). Dehydrated samples were treated for 5 min with 
hexamethyldisilazane (Electron Microscopy Supplies, Ft. Washington, Pa.), dried, mounted, and 
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sputter coated with gold (S150A sputter coater). Samples were viewed in a Hitachi H-300 
electron microscope with a 3010 scanning image accessory.  
For SEM immunogold labeling, spores were attached to poly-L-lysine coverslips and allowed 
to adhere for 30 minutes.  They were then rinsed in PBS with 50 mM NH4Cl, followed by a PBS 
blocking solution (1% BSA and 1% goat serum) for 5 minutes.   Anti-BclA rabbit polyclonal 
antiserum was diluted in PBS blocking solution (1:50) and added to the coverslips for 30 minutes 
at room temperature.  Two 5 minute washes in PBS plus 0.1% BSA followed.  15 nm colloidal 
gold conjugated goat anti-rabbit IgG antibodies (Aurion) were diluted 1:20 in PBS plus 0.01% 
fish gelatin and applied to the spores for 30 minutes at room temperature.  Three washes in PBS 
were performed, followed by fixation in 2% gluteraldehyde in PBS for 1 hour.   The coverslips 
were then washed twice in PBS buffer, and three times in distilled water. The spores were then 
dehydrated and treated as above. 
 
NO Assay 
 
 50 µl of media from each well of the infection study was taken at various intervals and 
placed in a 96-well plate.  To each well 50 µl of sulfanilamide solution (.33% w/v in 2.5% 
Phosphoric acid) and 50 µl of (.03% w/v in 2.5% Phosphoric acid) N-(1-
Naphthyl)ethylenediamine dihydrochloride solution were added to each sample.   Measurements 
were made using a Bioluminometer (Bio-Tek Synergy HT) at 500 nm.  The results of the assay 
were compared against a dilution standard of sodium nitrite. 
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Epi-fluorescence Microscopy 
 
5 mg of spores (wet wt.) were resuspended in StartingBlock (Pierce) and incubated at 
room temperature for 45 minutes with occasional mixing. The spores were then pelleted and 
resuspended in StartingBlock. Rabbit anti-BclA or anti-BclB polyclonal antiserum (1:250 
dilution) was then added and incubated at room temperature for 45 minutes with occasional 
mixing. The spores were washed 3X in StartingBlock and then incubated with (amount) FITC-
Protein A conjugate (Sigma Chemical Co.) and incubated for 45 minutes at room temperature 
with occasional mixing. The spores were subsequently washed 3X with StartingBlock, 
resuspended in PBS, and then examined by epi-fluorescence microscopy using a Nikon E600 
microscope.  
 
Spore Analysis by Flow Cytometry 
 
10 mg of spores were resuspended in 500 µl of 4% paraformaldehyde in PBS and 
incubated for 2 hours at room temperature. The spores were then washed 4X with PBS and then 
resuspended in StartingBlock and incubated with mixing at room temperature for 45 minutes. 
The spores were then pelleted and resuspended in StartingBlock. Rabbit polyclonal antiserum 
(1:250 dilution) against BclA or BclB was then added and incubated with mixing at room 
temperature for 45 minutes. The spores were then washed 3X in StartingBlock PBS and then 
incubated with mixing with FITC-Protein A conjugate (Sigma Chemical Co.) and incubated for 
45 minutes at room temperature. The spores were subsequently washed 3X with StartingBlock, 
followed by 2X with PBS and then processed on a FACScan flow cytometer using a 488 nm 
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argon laser (Beckton Dickinson Biosciences).  Data were analyzed using Cell Quest analysis 
software (Beckton Dickinson). For the ethanol-treated spores, the spores were resuspended in 
50% ethanol for 10 minutes and then pelleted and resuspended in StartingBlock. The treated 
spores were then exposed to the antiserum and FITC-Protein A as described above. 
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Results 
Mutant Strain Construction 
 
A precise in-frame deletion of the bclB determinant was created utilizing the splicing by 
overlapping extension (SOE) procedure (150, 151). Primers bclB 5pK 
(ggtaccgcagaaggaaaattaagttcg), bclB 3pS (gtcgacactaattcatctcgctttaac), bclB soeFB 
(aacaaaggatccctcattccacatttttgtttcctaattaac), and bclBsoeRB 
(caaaaatgtggaatgagggatcctttgttacaatgttaatagg) were obtained from Integrated DNA Technologies, 
Inc. (Coralville, IA) and used to amplify a DNA fragment consisting of the 1 kb sequence 
immediately upstream of the bclB open reading frame and the 1 kb sequence immediately 
downstream of this determinant. Flanking the PCR fragment are unique KpnI and SalI sites 
incorporated into the outer primers and a unique BamHI site at the position of the deleted bclB 
determinant. The cloned PCR fragment was verified by DNA sequence analysis at the University 
of Missouri DNA Core Facility. The ΩKan2 cassette (152) was inserted as a BamHI fragment 
into the unique BamHI site of the SOE product.  The Gram-positive replication region and 
erythromycin resistance marker from pUTE583 (153) was subcloned into the plasmid to create 
the mutagenic shuttle plasmid pGS3632 (Figure 6). The pGS3632 plasmid was passaged through 
the dam-negative E. coli host GM48 and electroporated into the ∆Sterne strain of B. anthracis by 
the method of Green et al. (154). Allele replacement mutants were obtained as described by Saile 
and Koehler (155). Electrotransformants were screened for resistance to kanamycin (50 µg/ml) 
and neomycin (25 µg/ml) and sensitivity to the vector encoded erythromycin resistance (5 
µg/ml).  
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 Figure 6: bclB knockout vector pGS3632 
 
Verification of the bclB mutant and the CTL292 bclA mutant.  
 
DNA was isolated from clones with the correct antibiotic-resistance phenotype and screened 
by PCR for the presence of the plasmid backbone (using primers pute5p cgataccgtcgacctcg and 
pute3p aacaaaagctgggtacc), an intact bclA region (primers bclA5pXm aacccgggctgaaggcaatgtatc 
and bclA3pS agcgtcgaccaattctctcctctag), and the bclB region (primers bclB5pK 
ggtaccgcagaaggaaaattaagttcg and bclB3pS gtcgacactaattcatctcgctttaac).   
A precise deletion of the bclB determinant was introduced into B. anthracis ∆Sterne-1 to 
create strain MUS1692. PCR analysis confirmed that the 1.1 kb bclB open reading frame was 
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successfully deleted and replaced with the 2.2 kb kanamycin resistance cassette as evidenced by 
the upward shift of the PCR amplicon (size increase of 1.1 kb.)  (Figure 7) Sequence analysis of 
the MUS1692 amplified DNA fragment confirmed its identity as the deletion allele. 
 
1      2     3     4
 
 
Figure 7: Left Panel: PCR analysis of the bclB null mutant of B. anthracis. Primers were 
designed to amplify a 2.9 kb fragment containing bclA (as a control; lanes 1 and 3) or a 4.0 kb 
fragment containing bclB. Lanes 1 and 2 are products from the ∆Sterne wild-type strain and 
lanes 3 and 4 represent products from strain MUS1692. The 5.2 kb band in lane 4 corresponds to 
the replacement of the 1.1 kb open reading frame with a 2.2 kb kanamycin resistance cassette.  
Right panel:  Demonstration of the replacement of the bclB gene with the kanamycin cassette.   
  
 
Chromosomal bclB (1.2 kb) 
Bam HI 
Kanamycin cassette (2.5 kb) 
Bam HI 
Kpn I Sal I 
pGS3632  
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Chromosomal DNA was isolated from the bclA mutant strain CTL292 (a gift from 
Charles Turnbough, Jr, 75) and PCR amplification was carried out with the primer pair 
5pbclAXh (aactcgagctgaaggcaatgtatc) and 3pbclAXh (aactcgagcaattctctcctctag) to amplify a 
DNA fragment whose ends were external to the deletion, and the primer pair qbclA5pB  
(cgggatccatgtcaaataataattatt) and qbclA3pS (agcgtcgacttaagcaactttttcaat) to amplify internal to 
the bclA open reading frame.  The internal deletion and the presence of the kanamycin cassette 
were verified by PCR and the shift of the amplicon from 2.8 kb to 3.9 kb in length. The junction 
of the deletion was also verified by the presence of a 120 bp product versus the 1.1 kb wild-type 
bclA ORF length, demonstrating the deletion of the collagen-like region (CLR) of bclA. (Figure 
7)   
1 2 3 4 5
Kanamycin 2.2 Kb
Wild-type bclA
1.1 kb
CTL292 bclA::kan
120 bp
N-Terminus
N-Terminus
C-Terminus
C-Terminus
 
 
Figure 8:  PCR analysis of the bclA mutant CLT292.   Left, PCR gel:   Lane 1, CTL292 bclA 
flanking regions,Lane 2, CTL292 bclA, Lane 3, DNA ladder, Lane 4, ∆Sterne bclA flanking 
regions, Lane 5, ∆Sterne bclA.  Right: Representative map of the bclA gene in CTL292. Blue 
arrows denote internal primer locations, Black, primers amplifying flanking regions 
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Electron microscopic examination of the spores lacking the BclB glycoprotein.  
 
Transmission electron microscopy revealed that the ∆bclB spores comprised a mixed 
population of spores. Many of the spores were morphologically identical to the parental strain 
spores (Fig. 9A). However, a number of spores with damaged exosporia were evident. The 
majority of these had ruptures of the exosporium layer, usually at one pole of the elliptical spore 
(Fig. 9B, 9C and 9F).  In addition, empty exosporia were evident in the mutant spore preparation 
(Fig. 9B, 9D and 9E), but were not present in the spores prepared from the wild-type parental 
strain. A large amount of debris that visually resembled exosporium material was abundant in 
spore preparations from the mutant strain, but not from the wild-type parent. (Fig 10A, 10B) 
Ruthenium red staining of the spores, which allows visualization of the glycoprotein outer nap 
layer of the exosporium (156), revealed that the surface glycoprotein, thought to be 
predominantly BclA, was present in both the mutant and wild-type spores. This dye also stained 
the debris material, supporting the idea that this material was shed exosporia. (Figure 10) 
  
Over two hundred spores from the ∆Sterne-1 and MUS1692 strains were examined from 
electron micrographs and the numbers of spores with an intact exosporium were calculated 
(Table 6). In a typical spore preparation, 95% of the wild-type spores appeared normal, whereas 
only 60% of the BclB-negative spores had a normal architecture. The remainder of the BclB-
negative spores displayed a damaged exosporium. The defect was either minor, with the damage 
usually at one pole of the spore, or severe with the spore either devoid or largely devoid of an 
exosporium layer. In addition, free exosporia are evident in the spore fields from the bclB mutant 
but were not observed in spore preparations from the wild-type spores. It appears that a 
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consequence of a lack of BclB production is the assembly of spores with a more fragile 
exosporium layer.  
 
 
3858 (25%)34 (15%)138 (60%)230bclB-
negative
019 (5.5%)0326 
(94.5%)
345∆Sterne
No. of 
empty 
exosporiab
Minor 
exosporium 
damage
Major 
exosporium 
damage
Normal 
morphology
No. of 
spores 
examined
Strain
 
Table 6: Intact spores from electron micrographs were counted and characterized. Minor damage 
is defined as an obvious rupture of the exosporium layer but with >50% of the exosporium 
remaining associated with the spore coat surface; major damage is defined as loss of more than 
half of the exosporium layer and includes the exosporium-negative spores.  
b:  Free exosporia numbers not included in the spore numbers or the damaged spore 
categories.  
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To determine the distribution of the BclB protein in the spore, immunogold labeling of the 
TEM samples was performed using goat-anti rabbit antibodies labeled with 15 nm colloidal gold 
particles.   Anti-BclB antibodies bound to the exosporium, as well as in the spore coat and spore 
cytoplasm (Fig. 11A).  Further analysis of the controls, where preimmune sera (Fig. 11B) or sera 
raised to a non-bacillus immunogen was used (data not shown), showed a low level of non-
specific binding in the cytoplasm and spore coat.  Non-specific binding was consistently found, 
but was always localized to the spore core and inner spore coat layers, and was not seen in the 
exosporium.  This supports the contention that the immunogold labeling of the exosporium was 
specific binding to the BclB protein.  The presence of an increased amount of immunogold label 
in the coat and core of the wild-type spores when compared to the control sera-treated spores 
suggested that BclB was present in those parts of the spore as well, and was not just localized to 
the exosporium.  Further evidence that BclB may also play a structural role in the spore coat was 
the appearance of what resembled sloughed off spore coat in the bclB mutant. (Fig 10B). 
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Figure 9:  Transmission electron micrographs of spores from the ∆Sterne strain (panel A) and 
the bclB-negative strain (panels B-F). In panel B, defects typical of a BclB-negative phenotype 
are illustrated including an exosporium-less spore (asterisk), ruptured exosporium (arrowhead) 
and empty exosporium (arrow). Panel C shows damaged exosporia and panels D and E (lower 
magnification) show the empty exosporia. Panel F is a higher magnification of a spore 
displaying typical damage to the exosporium which appears to be sloughing off the spore. 
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Figure 10:  TEM depictions of the free spore material.   Panel A: Arrow points to free 
exosporium-like debris.  Panel B: Arrow points to sloughed off material inside free exosporium, 
potentially spore coat.   
 
 
To further characterize the exosporium of the bclB-mutant spores and also to determine if the 
debris present in the BclB-negative spore samples was exosporium, immunogold labeling was 
performed with polyclonal anti-BclA sera.  In both the ∆Sterne and the BclB-negative spores, 
significant binding of the immunogold particles was found in the nap layer of the exosporium of 
the anti-BclA labeled spores (Fig. 11C, 11D). Both strains, when stained with anti-BclA and 
anti-BclB antibodies, displayed an increase in the labeling of the spore coat and cytoplasm 
relative to the immunogold labeling observed with the control sera.   Although other studies have 
not shown the presence of BclA in the spore coat and cytoplasm (75, 25), the use of a polyclonal 
antiserum (instead of monoclonal antibodies used in other studies) may explain the differences 
seen in these micrographs, as more epitopes can be recognized by the multivalent sera.  In 
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addition, the ruthenium red-stained exosporium-like debris found in the bclB mutant also reacted 
with the anti-BclA antibodies, further suggesting that this debris was shed exosporia (Figure 
10A).  
 
 
 
 
A                                  B                                      C                                     D 
 
Figure 11: TEM immunogold labeled spores.  A:  ∆Sterne spore labeled with anti-BclB 
polyclonal antisera and 15 nm colloidal gold beads.  B: ∆Sterne spore labeled with preimmune 
sera and 15nm gold beads.  C:  ∆Sterne spore labeled with anti-BclA polyclonal antisera and 15 
nm gold beads.  D:  MUS1692 labeled with anti-BclA antisera and 15 nm gold beads.  Arrows 
denote presence of gold beads.   
 
 
 
Changes in the outer surface of the BclB-negative spores were confirmed by scanning 
electron microscopy (Fig. 12). The majority of spores from the ∆Sterne strain (Fig. 12A) 
exhibited a smooth raisin-like surface with characteristic ridges similar to those observed by 
atomic force microscopy (12, 157). Many of the bclB-negative spores displayed a rougher, 
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dimpled appearance (Fig. 12B). A subpopulation of the BclB-negative spores contained ridges 
and had a distinctly wild-type appearance. This rougher appearance could represent the changed 
appearance of the disorganized exosporium layer itself in the bclB mutant, or alternatively, may 
signify a disruption of the exosporium layer and visualization of the underlying spore coat layers.  
The sloughed off material in the bclB mutant may well be exosporium (Fig. 12C). The presence 
of ridges on the spores was reported to signify a lack of an exosporium (12). To determine if the 
exosporium was still present in the bclB-negative mutant spores, immunogold labeling of the 
spores using rabbit anti-BclA polyclonal sera was carried out. Since the BclA protein is surface 
exposed in the exosporium layer loss of the exosporium would eliminate binding of the anti-
BclA antibodies. Immunolabeling demonstrated that the bclB-negative spores, despite their 
changed appearance, retained the exosporium as shown by the presence of surface-exposed BclA 
(Fig. 12D, E). There was a greater amount of debris associated with the mutant spores than was 
seen with the wild-type spores, presumably shed exosporium fragments.  To further validate the 
presence of BclB in the exosporium of spores as was observed by TEM, immunolabeling of 
wild-type spores for visualization by SEM was accomplished using anti-BclB sera. The presence 
of immunogold label on the spore surface further supported BclB being present in the 
exosporium (Fig 12F). However, the BclB-labeling of the spores occurred at a reduced level 
relative to the immunogold labeling that of BclA. This supported the hypothesis that BclB is 
present on the spore surface at a substantially reduced level compared to that of BclA. 
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Figure 12:  Scanning electron micrographs of the spores from ∆Sterne (Panel A) and the bclB-
deficient spores (B-F). Bars represents 1 micrometer.  The appearance of material sloughing off 
mutant spores is marked in Panel C by the white arrows.  Immunogold labeling of bclB-negative 
spores with anti-BclA antisera (D) and with overlaid backscatter image (E).  White arrows 
denote some of the sites where 15 nm gold beads are evident.  The black arrow in panel E points 
to gold bead labeling localized to sloughed off exosporium.  Panel F depicts ∆Sterne spores 
labeled with anti-BclB antibodies.  Arrows denote some of the sites of surface-bound antibody. 
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Resistance Properties of the Mutant Spores.  
 
The BclB-deficient spores were compared to the wild-type spores for resistance to heat 
(65˚C), ultraviolet irradiation (700 erg/mm2), organic solvents (chloroform, 5% phenol), and 
disinfectants (bleach, 1:32 dilution; and 95% ethanol).  No significant differences were observed 
in the resistance properties of the mutant versus wild-type spores except with chloroform, 
consistent with the resistance properties of the spores being a property of the spore coat layer 
(158), and the exosporium layer not substantially contributing to these resistance properties. 
(Figure 13)  Bleach was found to be a very efficient disinfectant for the sterilization of Bacillus 
anthracis spores. 
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Figure 13A: The bclB mutant and wild-type ∆Sterne spores and resistance to various insults.   
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Figure 13B (Continued)  
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Figure 13C (Continued) The bclB mutant and wild-type ∆Sterne spores and resistance to 
various insults.   
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Differential Protein Patterns in Spore Extracts from the bclB Mutant
 Equal amounts of spores from the MUS1692 strain and the ∆Sterne strain were boiled in 
SDS sample buffer for 10 minutes.  The spores were pelleted by centrifugation, and the 
supernatant was collected.  Proteins present in the supernatants were resolved by SDS PAGE on 
4-20% Tris-HCl protein gels.  The protein gels were stained with coomassie brilliant blue.  
Several unique bands differed in abundance between the extracts of the two strains. (Figure 14) 
Three protein bands were selected that differed between the two strains and cut from the gel and 
sent to the MU Proteomics core facility for MALDI-TOF MS/MS analysis and identification.   
The fourth high molecular weight band is presumed to be BclA, as this has been identified in 
many other studies (13, 15, 25, 80).   The MUS1692 strain had a greater abundance of the 
presumed BclA band running at ~220 kDa.   Results from the MALDI-TOF MS/MS protein 
identification are found in Figure 14.   Band 1, migrating at about 105 kDa, is comprised of the 
surface layer protein EA1.  This band has been shown to be a constant contaminate of spore 
preps, and despite extensive washing of the spores during purification, the presence of this 
protein persisted (13). 
Band 2, migrating at approximately 30 kDa, was comprised of several spore coat proteins in 
complex with one another.  Identified in the first band were the spore coat lytic enzyme CwlJ, 
the spore coat lytic enzyme SleB, and the germination protein GerQ.  All three of these proteins 
are found in conjunction with one another, and gerQ is essential for the presence of CwlJ in the 
spore coat (9, 11).  These proteins are essential for the degradation of the spore coat after spore 
association with a germination signal.  The bclB mutant had a significant increase in the amounts 
of these proteins in the spore extract.  These proteins were found in a series of heterogenous 
bands, due to their differing crosslinks between associated proteins (9, 11, 24).  The increase in 
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this band may indicate that the BclB protein plays a role in stabilizing the spore coat, as has been 
reported for other exosporium proteins (81, 85, 86).  This may explain the appearance of 
sloughed off spore coat in some of the TEM images of BclB-negative spores (Fig 10B). 
Band 3, migrating at about 20 kDa, was identified as immune inhibitor A metalloprotease. 
This protein has been found in the exosporium of all members of the Bacillus cereus family, and 
plays a role in the escape of Bacillus cereus and Bacillus thuringiensis from macrophages. (18, 
140) This protein was found to be greatly reduced in the bclB mutant spores.  The protein 
migrates as a band of 86 kDa, but is often found proteolytically cleaved (18). 
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Figure 14. Left Panel: Coomassie-stained protein gel.  Lane 1, rBclA protein; Lane 2, Prestained 
protein marker, top band 190 kDa; Lane 3, ∆Sterne spore extract, Lane 4, MUS1692 spore 
extract, Lane 5, prestained protein marker; Lane 6, rBclB.   
Right Panel:  Protein gel with bands identified by MALDI-TOF MS/MS.  The likely BclA 
protein band is marked.  Band 1 – EA1 S-layer protein, Band 2 – SleB, CwlJ, and GerQ spore 
coat lytic enzymes and germination proteins, Band 3, Degraded InhA1 protein. 
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Glycoprotein and Phosphoprotein Analysis of Spore Extracts
 Spore extracts of the MUS1692 and ∆Sterne strains of Bacillus anthracis were made and 
resolved by SDS PAGE.   Protein gels were collected and stained for either the presence of 
glycoproteins (Fig 15) using the Gel-Code Glycoprotein Staining kit (Pierce) or for 
phosphoproteins (Fig. 16) using the Pro-Q Diamond Phosphoprotein gel stain (Invitrogen).  
Presence of a high molecular weight band of about 220 kDa in both spore extracts was presumed 
to be the major glycoprotein in the exosporium, BclA.  Once again, the bclB mutant spore extract 
contained an increased amount of this 220 kDa band than did the wild-type spore extract.  Two 
minor glycoprotein bands appeared at 110 kDa and 90 kDa, which could either be the known 
exosporium glycoprotein ExsJ, (79), another exosporium glycoprotein, or partially glycosylated 
versions of BclA as seen in other studies (19).  In the operon adjacent to bclA, along with the 
spore carbohydrate biosynthesis genes that are predicted to glycosylate BclA, there is a 
serine/threonine phosphatase.  To determine if mature BclA or BclB is phosphorylated at their 
numerous threonine residues a phosphoprotein stain was performed on the spore extracts (Fig 
16).   There was a series of bands (approximately 43 kDa, 35 kDa, and 15 kDa) that appeared in 
the bclB mutant spore extract but not in the ∆Sterne spore extract.  The 35 kDa band most likely 
corresponds to the spore coat lytic enzyme proteins identified in Fig. 14.  There appeared to be a 
smear of phosphoprotein containing protein migrating at >180 kDa in the bclB mutant, whether 
this band is reproducibly obtained and if it is partially glycosylated BclA awaits further 
investigation.   
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Figure 15: Glycoprotein stained protein gel of spore extracts.   Lane 1, Prestained protein 
markers, top band 190 kDa.  Lane 2, rBclB; Lane 3, MUS1692 spore extract, Lane 4, ∆Sterne 
spore extract, Lane 5, rBclA.  Long arrow denotes likely BclA band.  Short arrows denote faint 
protein bands of approximately 90 and 110 kDa present in both spore samples.   
21 3 4
 
Figure 16:  Pro-Q Diamond Phosphoprotein stained protein gel of spore extracts.  Lane 1, 
protein marker with phosphoprotein at 60 kDa (long arrow).  Lane 2, MUS1692 spore extract, 
Lane 3, ∆Sterne spore extract, Lane 4, protein marker. (Differences in protein patterns are 
marked by small arrows. 
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Western Blot Analysis of the Mutant and Wild-Type Spore Extracts  
 
Two chemical methods have been described for extracting exosporium proteins from intact 
spores of B. anthracis. The simplest method is to boil the spores in SDS PAGE buffer. The 
second method involves extraction of the spores with 8 M urea. Although both methods have 
been shown to be efficient at extracting BclA from the spores, we found that only the urea-
extraction procedure reliably yielded the BclB protein from the wild-type spores (Fig. 17A, lane 
3).  SDS treatment resulted in lower recovery rates of BclB (data not shown). The BclB-reactive 
species were absent when the extracts were made from spores of MUS1692 (Fig 17A, lane 2), 
confirming the identity of the immunoreactive species in the ∆Sterne spores as BclB. Western 
blot results further suggested that the BclB protein is present in the exosporium, or on the surface 
of the spore coat, in spores of B. anthracis but in a configuration that is less extractable from the 
spore then by simple SDS treatment.  The BclB protein extracted from spores migrates in SDS 
PAGE as a high molecular weight heterogeneous population of bands. High molecular weight 
heteromers have been observed in spore extracts of B. anthracis and have been shown to consist 
of many exosporium-associated proteins that interact with BclA, BxpB, and ExsF (15, 19, and 
75). The migration properties of BclB suggest it may be part of similar complexes.  Most 
identified spore coat proteins are found as hetergenous species of molecular weights below 150 
kDa (55).  When anti-BclA antiserum was utilized to probe the spore lysates, the amount of BclA 
present in extracts from the bclB mutant spores was consistently greater (average of 2.3-fold 
based on 6 independent experiments) than the reactive material extracted from the wild-type 
spores.  (Figure 18) 
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Figure 17:  Western blot of spore extracts using rabbit anti-BclB polyclonal antiserum. Samples 
are: 1, protein standard markers; 2, urea extract from MUS1692; 3, urea extract from ∆Sterne. 
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Figure 18:  Western blot of spore extracts using rabbit anti-BclA polyclonal antiserum. Samples 
are: 1, protein standard markers; 2, SDS spore extract from MUS1692; and 3, SDS spore extract 
from ∆Sterne. 
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Surface Exposure of BclB on B. anthracis Spores.  
 
The anti-BclA and anti-BclB antisera were utilized to determine if the BclB protein is 
expressed on the surface of unfixed spores. Spores were incubated with the anti-BclA or anti-
BclB antisera followed by incubation with FITC-labeled Protein A. The spores were then 
extensively washed and examined by epi-fluorescence microscopy.  Results are shown in Fig. 
19.  Anti-BclA antibodies reacted strongly with the surface of the ∆Sterne and BclB-negative 
spores, consistent with the known surface location of this glycoprotein (Fig 19D and 19F). The 
anti-BclA sera did not react with the BclA deletion strain CTL292 (Fig 19E).  A fainter, but 
reproducible, signal was evident when the anti-BclB antiserum was incubated with wild-type 
spores (Fig 19G) but not with the bclB mutant spores (Fig. 19I). This suggested that the BclB 
protein is, at least in part, surface exposed in the spores of B. anthracis.  
Anti-BclA antibodies reacted strongly to the spore surfaces of both the wild-type and bclB 
mutant spores (19D and 19F).  Some spores in each population react strongly in this assay, 
whereas others displayed a uniform, but less intense, staining pattern.  This pattern was 
consistently observed with antibodies in excess, suggesting limitation of antibodies available for 
binding to the spores was not responsible for the staining differences observed.  Because the anti-
BclA antiserum was raised against recombinant BclA, the antibodies do not recognize the 
carbohydrate moieties of the glycoprotein.  Thus differences in glycosylation may explain the 
staining differences observed with individual spores.  The western blot results described above 
consistently indicated that the bclB mutant spores contained either more BclA or a more easily 
extracted BclA configuration than did spores of the wild-type strain (Fig. 18).  
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If BclB is present in the basal layer of the exosporium, binding of the anti-BclB antibodies 
could be hindered by the presence of the BclA hair-like nap blocking access to the BclB 
epitopes.  When the basal layer protein BxpB was identified, binding of the anti-BxpB antibodies 
was greatly increased when a bclA mutant strain was used (25).  We used the BclA-deficient 
strain CLT292 to examine the binding of the anti-BclB antibodies (Fig 19H).  When the CTL292 
spores were analyzed for the presence of BclB, a minor increase was seen in the binding of the 
anti-BclB antibodies. More notably, the anti-BclB antibodies concentrated at a point at the pole 
of the spore (Fig 19H). This polar concentration was not evident with the ∆Sterne spores (Fig. 
19G).  
 In agreement with the findings of the bclB mutant under TEM and SEM, there was 
evidence of damage to the exosporium layer of the mutant when examined by 
immunofluorescence (Fig 19F).   When the BclB-deficient spores were treated with anti-BclA 
antiserum, approximately 30-40% of the spores exhibited a lack of BclA-staining at one pole.  
This lack of BclA at one pole was most likely due to the damage of the exosporium layer at the 
pole, as was observed under TEM.  These spores appear to be devoid of the exosporium polar 
cap. There was also evidence of the exosporium being sloughed off and some spores devoid of 
staining altogether (Fig. 19G and data not shown).   
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Figure 19:  BclB is surface exposed in B. anthracis. Purified spores were treated with anti-BclA 
antiserum (panels A-C, and G) or anti-BclB antiserum (panels D-F) followed by FITC-protein A. 
Phase contrast images are shown adjacent to the fluorescence images (panels A-F). Panel G 
contains two merged anti-BclA fluorescence and phase contrast images to more clearly show the 
loss of fluorescence at one pole of certain spores. Spores were from the ∆Sterne strain (panels A 
and D), the BclA mutant CTL292 (panels B and E) or the bclB mutant MUS1692 (panels C, F, 
and G).  Image magnifications are 1000X. White arrowheads denote an increased concentration 
of the BclB protein at the pole of the spore.  White arrows denote spores missing BclA at the cap 
or pole and sloughing of exosporium. 
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Flow Cytometric Analysis of Spores
 
The fluorescence micrographs provided only a qualitative assessment of surface exposure of 
the BclA and BclB proteins. For a quantitative determination of BclA and BclB protein exposure 
on the spore surfaces, spores were subjected to analysis by flow cytometry utilizing the anti-
BclA and anti-BclB antisera. The results of these analyses are shown in Fig. 20. The results 
further demonstrated that BclB is surface exposed in the ∆Sterne spores and is absent in the 
spores prepared from the bclB-deletion strain (Fig. 20A and 20B). Furthermore, the flow 
cytometry analyses indicated the levels of BclA detectable on the surface of the bclB-mutant 
spores was increased relative to that of the wild-type spores, consistent with the western blot 
results (Fig. 18). The mean fluorescence intensity for the spore samples with anti-BclA 
antibodies was higher with the BclB-deficient spores (mean fluorescence of 187 versus 106). The 
amount of BclB exposed on the surface of the spores was substantially less than that of BclA, 
with a mean fluorescence intensity of 42. Loss of the BclB glycoprotein and its associated sugars 
from the exosporium may have resulted in a compensatory increase in the presence of the BclA 
glycoprotein, or a change in the structure of the exosporium which allows greater access of the 
BclA epitopes to the anti-BclA antibodies.  
 
A brief 10 minute exposure of spores from the bclB-deficient mutant to 50% ethanol 
followed by rehydration in PBS resulted in a shift in the staining with the anti-BclA antibodies 
(Fig. 20E), whereas this treatment had a negligible effect on the wild-type spores (Fig. 20F). The 
treatment of the mutant spores resulted in a small subpopulation of the spores showing increased 
fluorescence and a dramatic increase in the amount of material smaller in size than intact spores. 
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This BclA-reactive material appeared in a small size fraction, presumably representing free 
exosporium that had been stripped off of the mutant spores (lower left quadrant of Fig. 20E). 
Either the stress associated with the dehydration-rehydration cycle, or an effect of the solvent on 
the altered exosporium of the BclB-negative spores resulted in the physical removal of the 
exosporium material and its BclA nap from the spores.  
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Figure 20:  Flow Cytometry histograms. Paraformaldehyde-fixed spores stained with polyclonal rabbit 
antibodies and analyzed by flow cytometry.  In all figures the gray curve represents a spore control that 
was treated without the primary antibody. Percentage positive is marked for each sample, as well as the 
mean fluorescence intensity of all positive samples (signified by PMF).  A.  The black line represents a 
spore control treated without the FITC-protein A conjugate. The green line represents the BclB-negative 
mutant treated with anti-BclB antiserum.   B. The purple line represents ∆Sterne spores treated with anti-
BclB antiserum.  C. The green line represents the BclB-negative mutant with anti-BclA antiserum.  D.  
The purple line represents ∆Sterne spores treated with anti-BclA antiserum.   E.   The green line 
represents the BclB-negative mutant spores treated with anti-BclA antiserum after dehydration in 50% 
ethanol and rehydration.  F.  The purple line represents ∆Sterne spores treated with anti-BclA antiserum 
after dehydration in 50% ethanol and rehydration. 
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Effects of alcohol exposure and rehydration of spores is presented in Fig. 21, plotted to show 
size (forward scatter) along the x-axis and anti-BclA fluorescence along the y-axis. The BclB-
negative spores are shown in panels A and C and the wild-type spores are in panels B and D. 
Examination of the wild-type spore patterns indicated the spores stain heterogeneously with the 
anti-BclA antiserum/protein A-FITC. Almost half of the alcohol-treated spore population stained 
poorly with the antiserum (Fig. 21C). This pattern was maintained when a 5-fold increase in the 
amount of antibody was included, indicating that this staining pattern is not the result of a 
limiting amount of antibodies being present. The antiserum was generated against recombinant 
BclA and the immunogen lacked the glycosylation found on native BclA. Differences in 
glycosylation as well as differences between exosporium assembly (and BclA accessibility) 
between spores may explain the heterogeneity in binding by the anti-BclA protein antibodies. 
The brief exposure to 50% ethanol followed by rehydration had no effect on the wild-type spore 
staining pattern with either the anti-BclA antiserum (Fig. 21D) or with the anti-BclB antiserum 
(not shown). However, ethanol-treatment of the BclB-negative spores resulted in the appearance 
of larger amounts of debris in the sample, as shown in the lower left quadrant of Fig. 21C. 
Because this was not associated with a substantial increase in an unstained spore-sized 
population, it is likely that the single alcohol exposure removed fragments of the exosporium, but 
not the entire exosporium layer in these spores. 
The alcohol treatment may likely have accounted for the more dramatic change in 
appearance in the BclB-negative spores examined by scanning electron microscopy. A series of 
alcohol dehydration steps were involved in preparing the spores for SEM. 
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Figure 21:  Flow Cytometry Density Plots.  Paraformaldehyde-fixed spores stained with 
polyclonal rabbit antibodies and analyzed by flow cytometry.   A. BclB-negative mutant spores 
treated with anti-BclA antiserum.  B.  ∆Sterne spores treated with anti-BclA antiserum.  C.  
BclB-negative mutant spores treated with anti-BclA antiserum after dehydration in 50% ethanol 
and rehydration.  D.  ∆Sterne spores treated with anti-BclA antiserum after dehydration in 50% 
ethanol and rehydration 
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Spore-Macrophage Interactions.  
 
The presence of the exosporium on the outermost part of the spore leads it to potentially 
play a role in the initial interactions with the host; including phagocytosis by host macrophages, 
as well as outgrowth and escape from the phagosomes (13, 22).  The structural changes of the 
exosporium in the bclB mutant, and the loss of this spore-associated glycoprotein, may result in a 
change in the kinetics of survival of the mutated spores in macrophage cells. To assay uptake and 
infectivity of the bclB mutant spores vs. ∆Sterne spores in vitro; RAW 264.7 murine 
macrophages were infected at MOIs of 10:1 and 1:1 (spores/macrophage).  After treatment with 
gentamicin to kill off any free vegetative cells and inhibit growth of any unphagocytosed spores, 
samples were taken at timed intervals and plated for viable and heat-resistant colony counts. The 
total CFU would signify total phagocytosed and germinated spores and outgrown bacilli, while 
the heat-resistant viable count would signify ungerminated spores.  Counts of heat-resistant CFU 
versus heat susceptible CFU reveals that greater than 99% of all spores added to the media were 
heat-susceptible at 1 hr (data not shown).  At the first assayed time point of 1 hr, no significant 
difference was found between uptake efficiencies of the bclB-negative mutant spores versus 
∆Sterne spores.  Examination of viable CFUs at 1, 2, 4, and 24 hours revealed no difference in 
viable counts between bclB mutant and ∆Sterne spores.  A representative experiment is shown in 
Fig. 22.  Both strains were killed off with equal efficiency, with essentially zero viable cells 
remaining at 24 hours (based on 6 experiments). To assay the ability of ∆Sterne and bclB mutant 
spores to escape from macrophages, a free spore count was undertaken at various time points 
throughout the infection process.  Free spores appearing after gentamicin addition represent 
vegetative cells escaping from the macrophages, or more unlikely, slowly germinating spores.   
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Dixon et al. (39) reported that the presence of the pX01 plasmid is essential for escape from 
macrophages, but the results presented in Fig. 23 indicated that escape from macrophages 
occurred in both of our pX01-deficient strains, but at low amounts and these free cells were 
quickly killed off by the macrophages.   
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Figure 22:  Plate counts of lysates of RAW 264.7 cells infected with spores of the ∆Sterne strain 
(♦) or the bclB mutant spores (●). Values are expressed relative to the initial time point (1 hour 
post infection). Typical results of a 1:1 experiment are shown. Ratios of 1:1 and 10:1 
(spores:macrophages) were utilized with the same results. 
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Figure 23:  Plate counts of free vegetative cells from RAW 264.7 murine macrophages infected 
with spores of the ∆Sterne strain (Pink, yellow, and dark blue lines) or the bclB mutant spores 
(brown, purple, and teal lines). Values are expressed relative to the initial time point (1 hour post 
infection).  No significant differences in free spore counts were collected.   
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Additional Results 
 
Expression of His-Tagged Bcl Proteins. 
 
 The bclA and bclB ORFs were PCR amplified with primers with a BamHI restriction site 
on the 5’ primer and a SalI site on the 3’ primer.  (qbclA5pB cgggatccatgtcaaataataattatt and 
qbclA3pS agcgtcgacttaagcaactttttcaat for bclA, qbclB5pB cgggatccatgaaacagaatgacaaattatg and 
qbclB3pS agcgtcgacttagacgatattaagacctgc for bclB). The PCR products were cloned into the 
pCR2.1 Topo TA cloning vector system (Invitrogen).  After nucleotide sequencing to ensure the 
reading frame of the determinants was correct, the insert was digested and inserted into the 
pQE30 vector (Qiagen) utilizing the incorporated BamHI and SalI sites. The pQE30 plasmids 
encoding bclA (pBT3571) and bclB (pBT3642) were transformed into the M15 and AbleK E. 
coli strains harboring the pREP4 lacI repressor plasmid.    
 
 
Figure 24:  Plasmid maps of the BclA and BclB protein expression vectors. 
 111
 IPTG-induced expression of the BclA and BclB His-tagged proteins was conducted for 3 
hours, as suggested by the Qiagen protocol for optimal protein production.  Yields of protein 
were, however, minimal.  A growth curve was established for both the pBT3571 and pBT3642 
plasmid-bearing strains in both the M15 and AbleK backgrounds (Figure 25). No growth 
difference was seen between the two plasmid-bearing strains.  When the E. coli was induced by 
the addition of 1 mM IPTG to produce the recombinant proteins, a quick cessation in growth was 
observed within 30 minutes of induction.  Growth of the cultures stalled indefinitely in both the 
M15 and AbleK strains. The M15 strain of E. coli reached the O.D.600 of 0.6 more quickly than 
the AbleK strain, potentially due to its higher plasmid copy number; but after induction the 
AbleK strain was able to reach a higher O.D. before stalling in growth.  This slight increase in 
O.D. may explain the increased protein production obtained in the AbleK strain over the M15 
strain.  Only a modest inclusion body formation was seen in each strain (data not shown). 
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Figure 25:  Growth curves of E. coli expressing rBclA and rBclB.  Top Left Panel, Growth of 
the M15 strain with either: no construct, the BclA construct, or the BclB construct, with or 
without IPTG induction at OD 0.6.  Top Right Panel, Growth of the Able K strain with either:  
no construct, the BclA construct, or the BclB construct respectively, with or without IPTG 
induction at OD 0.6.  Bottom Left Panel, Comparison of growth between the M15 and Able K 
strains with the rBclA construct with or without IPTG induction.   Bottom Right Panel, 
Comparison of growth between the M15 and Able K strains with the rBclB construct with or 
without IPTG induction.  Note the cessation of growth after IPTG induction in all cases.   
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Proteins produced were analyzed by SDS PAGE, and migration rates were compared to 
expected sizes.  Both rBclA and rBclB migrated as a species much greater than expected, but this 
has been seen in many bacterial proteins with high proline content (95, 96).  The rBclB protein 
migrates as two bands (85 and 105 kDa). The reason for this is unknown at this time.  rBclA 
migrates with a larger apparent molecular weight (65 kDa), as previously reported (15). 
 
 
 
 
1 32
 
Figure 26: His-tag column purified proteins from Able K induced with IPTG for one hour. Lane 
1, rBclB, Lane 2, rBclA, Lane 3, Protein Ladder (190 kDa, 100 kDa, 80 kDa, 70 kDa, 60 kDa, 50 
kDa, 40 kDa, 30 kDa)   
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Sporulation Efficiencies. 
 
 To test the ability of the bclB mutant to sporulate, several sporulation assays were 
performed.  Overnight cultures of live cells were inoculated into fresh BHI until the O.D.600 
equaled 0.2.  500 ul of the cultures were used to inoculate Difco sporulation broth (into 9.5 ml) 
and allowed to go at 37oC.. The results are presented in Table 7. Two strains of Bacillus 
anthracis that either did not sporulated (spore -) or that sporulated rapidly (spore ++) were used 
as controls.   There was a significant difference between the bclB mutant and the ∆Sterne strain 
in sporulation efficiencies, with no released spores seen in the bclB mutant and full sporulation 
of cells seen in the ∆Sterne strain at 5 days.  This was tested by observation under light 
microscopy, as well as by heat resistance to 60oC to assay percent spores.  
 
 
 
∆Sterne bclB mutant Spore - Spore ++
Media Spore Broth Spore Broth Spore Broth Spore Broth
24 Hours
Sporulation Perecentage 60.50% 0.10% 0% 45%
48 Hours
Sporulation Percentage 63.40% 2.60% 7.60% 97.30%
Table 7: Sporulation in spore broth, based on heat resistance at 65oC for 30 minutes 
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 To further test this difference in sporulation efficiencies, fresh inoculums were used to 
test sporulation in different medias and at different temperatures, and micrographs taken at each 
timepoint to assay sporulation and release of spores.  In Difco sporulation broth, the ∆Sterne 
strain started sporulating in less than 24 hours, with the majority of spores being released 
between 48-72 hours, and consisted of greater than 95% free spores when observed at 5 days 
(Figure 27).  In contrast, the bclB mutant did not start to sporulate at all, and started to lyse at the 
72 hour time point, with death of the filaments and no spore production at 5 days.  (Fig 27) 
 
A B 
C D 
Figure 27: Sporulation in Difco sporulation broth, 5 days. Growth at 30oC (A and B) and 37oC 
(C and D) of ∆Sterne (A and C) and MUS1692 (B and D).  Phase bright spores are evident in the 
∆Sterne panels, but not in the MUS1692 panels.  Evidence of cell lysis is present in the 
MUS1692 panels. 
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  Another alternative to sporulation broth is nutrient broth.  This low nutrient broth induces 
sporulation in little time in Bacillus species (data not shown).  In nutrient broth the results were 
comparable with sporulation broth with ∆Sterne completely sporulated at 5 days, and lysis of the 
bclB mutant strain at 48-72 hours. (Figure 28) In both of the broths more spores were produced 
at 37oC than at 30oC, potentially due to the higher O.D. reached before sporulation was initiated 
(data not shown). 
 
A B 
C D 
Figure 28: Sporulation in nutrient broth, 5 days. Growth at 30oC (A and B) and 37oC (C and D) 
of ∆Sterne (A and C) and MUS1692 (B and D).  Phase bright spores are evident in the ∆Sterne 
panels, but not in the MUS1692 panels.  Evidence of cell lysis is present in the MUS1692 panels.   
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  A different phenotype was observed from analysis of spores that were streaked onto 
nutrient agar or sporulation agar plates.  In both strains, under growth at 30oC, spores were 
observed as early as 24 hours.  By 48 hours, more than half of the cells sporulated and released 
their spores.  No conceivable difference was seen between the two strains through 5 days. 
(Figure 29)   Interestingly, this was not the case when sporulation was induced at 37oC on agar 
plates.  (Figure 29)  The ∆Sterne and bclB mutant strains appeared similar in both the broth 
sporulation assays, but with a decrease in free spore number seen in the ∆Sterne strain.   The 
bclB mutant once again lysed out at 48-72 hours with little to no spores produced.  The summary 
of these results is shown in Table 8.  Efficient sporulation in both strains was only induced by 
growth on nutrient or spore agar plates at 30oC.   Sporulation in the bclB strain is dependent on 
temperature and on the media supplied.   Part of this dependency is oxygen availability.  When 
bclB mutant cells were inoculated in small volumes of broth in an oversized flask under high 
RPMs, to maximize exposure to oxygen, they sporulated with kinetics similar to ∆Sterne. (Table 
8) 
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 A B 
C D 
Figure 29: Sporulation on nutrient agar, 5 days. Growth at 30oC (A and B) and 37oC (C and D) 
of ∆Sterne (A and C) and MUS1692 (B and D).  Phase bright spores are evident in the ∆Sterne 
panels and MUS1692 panel at 30oC, but not in the 37oC MUS1692 panel.   
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∆Sterne ∆Sterne ∆Sterne ∆Sterne bclB mutant bclB mutant bclB  mutant bclB mutant
Media Spore Broth N Broth N Agar Spore Agar Spore Broth N Broth N Agar Spore Agar
24 Hours
Sporulation Percentage 30oC 2% 2% 30% 40% 0% 0% 10% 40%
Sporulation Percentage 37oC 40% 15% 20% 20% 0% 0% 0% 20%
48 Hours
Sporulation Percentage 30oC 15% 8% 40% 50% 0% 0% 35% 50%
Sporulation Percentage 37oC 30% 35% 40% 35% 0% 0%, lysis 0% 20%
72 Hours
Sporulation Percentage 30oC 55% 30% 65% 95% 0%, lysis 0%, lysis 65% 95%
Sporulation Percentage 37oC 90% 95% 45% 70% 0%, lysis 0%, lysis 2% 20%
5 days
Sporulation Percentage 30oC 95% 75% 95% 95% 0%, lysis 2% 95% 95%
Sporulation Percentage 37oC 95% 95% 80% 85% 0%, lysis 0%, lysis 5% 25%
Table 8:  Sporulation efficiencies, assayed by visualization under light microscopy and 
observation of free, phase bright spores.    
 
Infection Study Controls 
 
Before undertaking the infection of macrophages with the spores, the ability of the spores 
to germinate in the media needed to be assayed.   The spores in the presence of the cell culture 
media alone did not germinate. (Table 9)  Further analysis of the defined cell culture media 
DMEM + low glucose (Eagle) revealed that the media did not contain any of the germinants 
necessary for proper germination and outgrowth of the spores.  When the heat-inactivated FBS 
was added to a final concentration of 10%, the spores took off and multiplied rapidly, with >85% 
of the spores germinating within one hour, and a doubling time of roughly 30 minutes not 
including time allotted for outgrowth.  Since germination occurs quickly in the DMEM + 10% 
heat-inactivated FBS, the spores were centrifuged down to rest upon the macrophages, and are 
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quickly engulfed within 5-10 minutes.  (data not shown)   To assay whether the gentamicin could 
efficiently kill any germinating and outgrown cells, a Minimum Inhibitory Concentration (MIC) 
of gentamicin was obtained by inoculating DMEM plus 10% FBS with serially increasing 
concentrations of gentamicin.  The MIC of gentamicin under these conditions was 2.5 ug/ml.  In 
the presence of media plus macrophages, the germination of spores was even greater, with 
almost all the spores germinating within one hour of inoculation. (Figure 30) Whether this was 
due to secretion of germinants by the macrophages, or by uptake of the spores into the 
macrophage where conditions are more suitable for germination is unknown.   
 
Spores Media alone Media + FBS
Input spores 1000 1000
DS 1002 3698
DS ungerminated spores 1180 232
BclB 1587 4395
BclB ungerminated spores 1500 255
∆Sterne   (2.5 ug/ml) 
BclB  (2.5 ug/ml) 
 
 
Table 9:  Germination efficiencies in DMEM media + low glucose, and DMEM + low glucose + 
10% heat-inactivated FBS.   Total CFU and heat resistant CFU (spores) as annotated separately.  
Input spores is an estimate.  The MIC of gentamicin is indicated in the lower portion of the table 
in both strains.  
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∆Sterne ∆Sterne bclB mutant bclB  mutant
Media MOI 1:1 MOI 10:1 MOI 1:1 MOI 10:1
1 Hour
Germination % 99% 97% 95% 92%
2 Hours
Germination % 99% 99% 99% 99%
Figure 30: Germination of spores in DMEM + low glucose and 10% FBS in the presence of 
RAW 264.7 murine macrophages.  Germination was determined by heat sensitivity to 65oC for 
30 minutes. 
 
Nitric Oxide Release 
 
 Due to the success of the macrophages in elimination of spores, an assay was performed 
to test for whether the macrophages were being activated by the presence of the spores or 
potentially from contaminating LPS or residual activators.   Activation of macrophages, due to 
signaling by TLRs, cytokine messages, or other stimuli leads to a dramatic increase the 
macrophages’ ability to kill Bacillus anthracis spores (39). This activation leads to the 
upregulation of NO and related free radical species in the macrophage, and the NO can be 
assayed via the Greiss reaction.  The disruptions in the exosporium in the bclB mutant spores, 
along with recent studies showing the protective effect of the exosporium in preventing access to 
stimulators of the immune system and secretion of cytokines by macrophages lead us to assay 
the NO concentration in the media around the macrophages (141).  Ratios of spores:macrophages 
greater than 10:1 are required for NO release in the avirulent ∆Sterne and MUS1692 strains.  The 
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only increase in NO production was seen at a MOI of 100:1 after 24 hours.   The addition of 
Nystatin or gentamicin had no effect on NO production (data not shown)  
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Figure 31:  NO release by macrophages under different MOIs of ∆Sterne and MUS1692 spores 
for 24 hours.  Total spore CFU is denoted to the right of the strain, infecting 1x106 macrophages 
per well.   
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Promoter Analysis
  
The promoter for both bclA and bclB were collected from the TIGR Microbe Genome 
Database.  Selection of the promoters was accomplished by analyzing the region between the 
start codon of each gene and the region upstream until the next ORF was met.  The selected 
putative promoter regions were analyzed for the presence of the well characterized Bacillus 
subtilis late sporulation gene and other sigma factor binding sites.  Both genes had several 
putative σK-like promoter elements, comparable to analysis of the promoters of other late 
sporulation genes in Bacillus anthracis (ExsF, ExsY, CotY).  A recent genome wide microarray 
data set (54) was analyzed for the upregulation of late sporulation genes, many in adjacent 
operons to bclA.  bclA and bclB, as well as several other related late sporulation genes were 
upregulated concurrently with σΚ.  (Figure 31, 32) 
 B
 
AS1130  promoter sequence (BclA)  
 
TAATCACCCTCTTCCAAATCAATCATATGTTATA
 
 
 
CATATACTAAACTTTCCATTTTTTTA
AATTGTTCAAGTAGTTTAAGATTTCTTTTCAATAATTCAAATGTCCGTGTCATTTTCTTTC
GGTTTTGCATCTACTATATAATGAACGCTTTATGGAGGTGAATTTATGTC 
RED- PERFECT MATCH 
BLUE – ONE OFF, -35 
GREEN-RBS 
BAS2281 promoter sequence (BclB)
 
 
      
 
ATTAGAACGTAACCAATTTAGTATTTTGAAATAGAGCTATCATTTTATAATATGAATA
CTACTAGTTATAGAAACGGCAAAAAGTTTAATATATGTAAAAATCATTTGGA
CATAGATTT
TATGAAA
AAAGTAGC TTT
 
 
CGAAATGATAAATGTTTTATTTTGTTAATTAGGAAACAA
AAATGTGGAATGAGGGGGATTTAATTGAAACAGAA 
RED-THREE OFF 
BLUE – THREE OFF, OR TWO OFF WITH 16 SPACER 
TWO OTHERS WITH THREE OFF 
GREEN-RBS 
Figure 32:  Promoter analysis of bclA and bclB.  The putative σK binding sites are denoted in 
various colors with the number of imperfect matches to the Bacillus subtilis consensus sequence.   
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Figure 33: Transcription profiling of the bclA and bclB genes, as well as the operons adjacent to 
bclA.  Adapted from Bergman et al. (54) 
 
TEM in vegetative cells 
 
 Sporulating cells were analyzed by TEM in the process of sporulation to look for defects 
in the appearance of the exosporium inside the developing cell.  Preliminary results show no 
discernable difference in the exosporiums of developing spores.  
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Fig 32 
 
 
 
 
 
A B
Figure 34: TEM Micrographs of developing spores. A: ∆Sterne spores. B: MUS1692 spores. 
 
Urea vs. SDS 
 
 Analyses of the two methods for extraction of proteins from the exosporium were 
analyzed.  First, western blots were performed on ∆Sterne spores and bclB mutant spores that 
had been boiled in either urea extraction buffer or SDS sample buffer.  Results using anti-BclA 
antisera are presented in Figure 35.   There was an increase in both the BclB and BclA proteins 
extracted using the urea buffer extraction technique (Figure 35 and data not shown).  
Interestingly, the migration rate of BclA differs significantly between the two methods, with an 
increase seen when BclA was extracted with urea (figure 35).  One explanation is that the 
treatment of spores with urea may enable BclA to keep incorporated with BclA-associated 
proteins, but under treatment with SDS, the BclA comes off as clean trimers.   
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Spores that had been boiled in either buffer were washed several times in PBS, and 
analyzed using both immunofluorescence (Figure 36) or by examination by TEM (Figure 37).  
After boiling of spores in SDS, no discernable damage was evident on the spores, but a general 
loss of fluorescence was observed (Figure 36 A-D).  After boiling in urea buffer, the spores took 
on a fuzzy appearance, with a halo of fluorescent material coming off many of the spores (Figure 
34 E and F).  This fuzzy appearance was more dramatic under TEM, and the appearance of the 
nap and exosporium changed dramatically after urea treatment (Figure 35).  SDS treatment had 
minor effects of the exosporium.    
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5
Figure 35:  Western blot using anti-BclA antisera.  Lane 1, ∆Sterne spores boiled in SDS sample 
buffer, Lane 2, MUS1692 spores boiled in SDS sample buffer, Lane 3, protein marker, Lane 4, 
MUS1692 spores boiled in urea buffer, Lane 5, ∆Sterne spores boiled in urea buffer.   
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 ∆Sterne bclB mutant
Anti-BclA
Anti-BclA 
+ SDS
Anti-BclA 
+ Urea
C
A
E F
D
B
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 36: Immunofluorescence of spores with anti-BclA antisera before (A and B) or after 
boiling in SDS (C and D)  or Urea buffers (E and F).  Samples are ∆Sterne (A, C, and E) or 
MUS1692 spores (B, D, and F). 
 
 
 
 128
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TEM fig 35 
 
A B
C D
Figure 37:  TEM of spores untreated (Panels A and B) or treated with SDS (Panel C) or Urea 
buffer (Panel D). An arrow denotes the fuzzy, modified appearance of the exosporium after 
boiling in urea buffer.   
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DISCUSSION 
  
Much of what we know about spore maturation was learned from studies with Bacillus 
subtilis and its well defined genetic systems. However, B. subtilis does not possess either a 
distinct exosporium layer or BclA- or BclB-like proteins. Thus no information is available from 
the B. subtilis literature to extrapolate to the assembly of this outermost spore layer in B. 
anthracis. The exosporium is a prominent spore feature of organisms of the B. cereus family, a 
group comprised of animal and insect pathogens. The exosporium layer may therefore be 
important for spore interactions with host cells.  
 
BclB has many similarities to the well-characterized exosporium glycoprotein BclA.  Like 
BclA, it also contains an internal collagen-like tandem repeat (GITGVTGAT).  As in BclA, the 
repeated threonines in the BclB repeat are the likely sites of glycosylation, and the BclB-
associated sugars rhamnose, 3-O-methyl rhamnose, and galactosamine have been identified.  
Recent microarray data showed that both bclA and bclB are transcribed simultaneously during 
sporulation (54).  The bclA and bclB determinants are both preceded by σK-like promoter 
sequences and expression of these genes initiates late in sporulation (54). Both glycoprotein 
determinants are expressed in conjunction with the rhamnose determinants in the operon adjacent 
to bclA, also containing a σK-like promoter element.  This expression pattern is consistent with 
expression from promoters regulated by this late mother-cell-specific sigma factor and is 
consistent with the placement of BclB in the outer spore layers. 
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 Under SEM, the bclB mutant appears to have a more dimpled appearance, with a decrease in 
the presence of the pronounced ridges found in the wild-type spores.  Chada and coworkers 
utilized atomic force microscopy to characterize spore surfaces and suggested that the presence 
of ridges in spores signifies the loss of the exosporium layer (12).  Using anti-BclA sera, our 
immunogold-labeled spores appeared to be encased within an exosporium as evidenced by the 
presence of the surface-exposed BclA. The presence of the BclA-containing exosporium was 
independent of the appearance of the ridges on the spore surface. Loss of the BclB protein has an 
impact on both the integrity and stability of the exosporium, as well as modifying the appearance 
of the exosporium under SEM.   
 
Examination of material extracted from spores further supports our conclusion that BclB is 
associated with the exosporium.  Other exosporium-associated proteins when extracted and 
subjected to SDS PAGE analysis have been found to co-migrate with BclA in a heterogenous 
band of >200 kDa.  The presence of BclB migrating in similarly sized complexes further 
suggests its association in similar complexes. The decreased yield of BclB from spores suggests 
that it is present at a lower concentration then BclA, or is more securely anchored than BclA. 
 
We have found that BclB is surface exposed on the spores of B. anthracis.  It has been shown 
that antibodies can not cross the exosporium, suggesting that BclB is in the exosporium and not 
residual fluorescence from the spore coat (159).  By immunofluorescence we have shown a 
consistent binding of our anti-BclB antibodies to the surface of spores. The intensity of the 
binding is less than that observed with anti-BclA antibodies. The heterogeneity of the 
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fluorescence of the spores with anti-BclA antibodies could be explained by the differing 
accessibilities of the antibodies to the protein backbone epitopes of BclA due to the differing 
glycosylation patterns, or may support a nonuniform assembly of the exosporium, as recently 
described (97).  
 
 The length of the surface filaments on the exosporium surface correlates with BclA repeat 
number and bclA-negative spores possess no visible hair-like nap layer, indicating that the nap is 
largely composed of this protein (15, 19). Immunofluorescence studies reported herein indicate 
that the BclB glycoprotein is also surface exposed on the spore and plays a role in the structural 
integrity of the exosporium layer as indicated by the increased fragility of this layer in spores 
lacking this protein.  The fact that the bclA mutant spores are devoid of a noticeable nap does not 
rule out the possible presence of BclB in the nap.  The lower content of BclB expressed on the 
exosporium may not produce visible filaments without the presence of BclA.    Loss of BclB and 
its associated sugars could leave architectural voids within the exosporium nap layer that are 
selectively filled with BclA and may lead to an increase in BclA incorporation and the relative 
increase in BclA as seen on western blots and immunofluorescence.  Alternatively, loss of BclB 
could also open up gaps in the nap that better allow antibodies access to BclA epitopes or could 
orient the BclA protein in a way that can be more easily extracted from the exosporium.    
 
The loss of the BclB glycoprotein from the exosporium and possibly from other sites within 
mutant spores leads to a more fragile exosporium layer.  Examination of the BclB-negative 
spores under TEM and by immunofluorescence demonstrated that often this fragility is at one 
pole of the spore.  BclB was found to localize in greater amounts at one pole of the cells in the 
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CTL292 bclA deletion strain, suggesting that BclB accumulates at the pole of the spore, or 
potentially in the cap structure described by Turnbough and coworkers (75, 97).   If the BclB 
protein has a structural role at the pole of the exosporium, lack of BclB at this site may lead to 
the polar damage seen in the TEM and immunofluorescence micrographs.   Stress of the 
exosporium may lead to breakage at the pole.  The exosporium cap has been reported to be a 
weakened spot in the exosporium where newly germinated cells emerge (97).  BclB may play a 
role in strengthening or anchoring the cap, and lack of BclB could lead to a weaker cap that pops 
off more easily.  When BclB-negative spores were stained with anti-BclA sera, many of the 
spores exhibited no staining at one pole. We interpreted this as a lack of exosporium at the pole 
and not a lack of antibody staining, consistent with the damage seen in the TEM micrographs. 
The percentage of spores with damage seen under TEM is roughly equal to the percentage of 
mutant spores seen under Immunofluorescence without polar staining or a cap.  Without the 
exosporium at the cap or pole, the exosporia may slough off, as is evident under TEM.  These 
sloughed off exosporia may be more susceptible to extraction, leading to the increased amount of 
BclA found in the BclB-negative spores by western blot.    
 
The effects of ethanol exposure and presumably the dehydration/rehydration process may 
underscore the significant role of BclB in the architecture of the exosporium.  Since BclB may 
play also play a role in the flexibility of the exosporium, the ∆BclB mutant may lose this 
flexibility causing increased breakage of the exosporium when stressed by the 
dehydration/rehydration of the spore.    
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BclB plays a role in the structural integrity of the exosporium.  The influence of BclB on the 
incorporation of the BclA protein and on the overall architecture of the spore, directly or 
indirectly, is one of the keys in the formation or maintenance of a rigid and complete exosporium 
structure in B. anthracis.    
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